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ABSTRACT OF THE DISSERTATION 
Perinatal Nicotine Exposure and Programming of HIE Sensitive 
Phenotype in Neonatal Rat Brains 
 
Yong Li 
Doctor of Philosophy, Graduate Program in Pharmacology 
Loma Linda University, June 2013 
Dr. Lubo Zhang, Chairperson 
 
Large epidemiological and animal studies have revealed a clear association of 
adverse intrauterine environment with the increased risk of metabolic, cardiovascular and 
neurological diseases. Maternal smoking is the single most widespread perinatal insult in 
the world and has been associated with adverse pregnancy outcomes for mother, fetus 
and the newborn. Our study aims to test the hypothesis that perinatal nicotine exposure 
induces reprogramming of susceptibility to hypoxic ischemic brain injury in the 
immature brain, focusing on the roles of AT1R and/or AT2R and trying to reveal the 
underlying epigenetic mechanisms. Therefore, we established two rat models: perinatal 
nicotine exposure model in time-dated pregnant rats; hypoxic-ischemic encephalopathy 
(HIE) in 10-day-old rat pups. In the first part of our study, we demonstrated that nicotine 
exposure induces aberrant brain development in P10 pups, downregulating AT2R 
expression in male but upregulating AT2R in female pup brain, enhancing brain 
vulnerability to HIE in a sex-specific manner. In addition, we observed both AT1R and 
AT2R are implicated in the pathogenesis of neonatal HIE and confers neuroprotective 
property; AT2R plays the pivotal and causal role in nicotine induced sex-dependent 
alteration of vulnerability to HIE in the developing rat brain. Our further study focused 
on the epigenetic mechanisms involved in nicotine exposure mediated pathological 
effects in HIE. We demonstrated that perinatal nicotine exposure causes heightened 
xv 
methylation status of a single CpG adjacent to TATA-box at AT2R promoter, inhibiting 
TBP and recruiting MeCP2 binding, repressing AT2R gene expression, contributing to 
the enhanced vulnerability to HIE brain injury in male rat pups. All of pathological 
effects are reversed by administration of 5-Aza, a well-known DNA methylase inhibitor. 
These findings provide new insights in understanding of the pathogenesis of HIE in 
newborns and may suggest potential targets for the prevention and treatment of HIE, one 
of the most common causes of brain damage with severe mortality and long-lasing 
morbidity in infants and children.     
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CHAPTER ONE 
INTRODUCTION 
Numerous epidemiological, clinical and experimental studies have shown clearly 
that a compromised intrauterine environment may have subtle or drastic impact on 
tissue/organ ontogeny, structure and function, and alter the vulnerability or resiliency to 
some challenges and diseases in later life (Cottrell and Seckl, 2009; Dudley et al., 2011). 
A wealth of evidence has indicated that an adverse fetal environment, mostly manifested 
as intrauterine growth restriction (IUGR), is closely associated with increased risks of 
development of hypertension, coronary heart disease, insulin resistance, type 2 diabetes, 
central obesity, hyperlipidaemia, and other neurobehavioral, neuropsychological and 
neuropsychiatric disorders in adulthood (Barker et al., 1993a, 2009; Dudley et al., 2011; 
Gluckman and Hanson, 2004; Gluckman et al., 2008; Harris and Seckl, 2011). 
Environmental signals can be transmitted from the mother to the fetus, impacting specific 
vulnerable tissues in their sensitive developmental stage, modulating normal development 
trajectory, remodeling their structure and function and reprogramming the resiliency or 
susceptibility to diseases in postnatal life (Harris and Seckl, 2011). As one of critical 
targets of various stressors, brain is the central organ responsible for stress responses, 
determining the adaptive or maladaptive responsiveness to various acute or chronic 
stressful conditions via making corresponding alterations in its structure and function 
(McEwen, 2008). The developing brain in the fetal and neonatal stage is highly plastic, 
flexible, and especially sensitive to numerous adverse environmental factors. Combined 
2 
with specific genetic traits, these changes of fetal and neonatal brain may contribute to 
high incidence of a broad spectrum of neurodevelopmental disorders in the postnatal life.  
Perinatal stresses, such as hypoxia, malnutrition, substances exposure and excess 
glucocorticoid (endogenous or exogenous), have long lasting impact on the developing 
brain; altering brain’s ontogeny, organization, structure and function; remodeling brain’s 
development trajectory, and reprogramming brain’s vulnerability or resiliency of some 
neurobehavioral, neuropsychological and neuropsychiatric disorders in later life (Archer, 
2011; Chen and Zhang, 2011; Chiriboga, 1998; Harris and Seckl, 2011; Seckl and 
Meaney, 2004; Zhang et al., 2005).    
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of major causes of acute 
mortality as well as chronic neurological disability in newborns (Chen et al., 2009b; 
Vannucci, 2000). However, up to now, no universally accepted therapy is available for 
HIE except that a few studies implied that moderate hypothermia, administered in the 
early phase for full term neonates with mild or moderate encephalopathy, may reduce 
mortality and disability at 18 months (Perlman, 2006; Rees et al., 2011). Although the 
underlying mechanisms of heightened brain vulnerability to hypoxic–ischemic (HI) 
injury in newborns remain largely elusive, recent studies suggest a possible cause of 
aberrant brain development due to fetal insults (Jensen, 2006). It is well-known that 
maternal cigarette smoking is the single most widespread perinatal insult in the world. As 
one of the major components in cigarette smoking, nicotine readily crosses the placenta 
and produces higher nicotine concentrations in the fetal circulation than that experienced 
by the mother (Lambers and Clark, 1996). Recent studies have provided evidence linking 
perinatal nicotine exposure and the increased incidence of neurodevelopmental disorders, 
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neurobehavioral deficits, impaired cognitive performance, and increased risk of affective 
disorders later in life (Wickstrom, 2007; Pauly and Slotkin, 2008). However, whether and 
to what extent perinatal nicotine exposure adversely affects the brain susceptibility to 
neonatal HI injury in newborns remains unknown. Emerging evidence has revealed that 
the brain renin-angiotensin system (RAS) plays a vital role in the development and 
progression of cerebrovascular diseases, and both angiotensin II type 1 (AT1R) and type 2 
(AT2R) receptors are pivotal players in the pathogenesis of ischemic brain injury, which 
may also implicate in neonatal HIE (Sokol et al., 2004; Schrader et al., 2005). Therefore, 
it is tempting to speculate that maternal stresses including perinatal nicotine exposure 
may impact normal brain development of fetus, specifically reprogramming some key 
genes expression patterns such as  angiotensin II type 1 (AT1R) and type 2 (AT2R) 
receptors and contributing to alteration of the vulnerability to some challenges later in 
postnatal life. 
  
Developmental Programming of Health and Disease 
 Fetal growth and development are a complex and dynamic process that depends 
on sophisticated interactions among the mother, placenta and fetus to ensure optimal 
growth and survival conditions (Warner and Ozanne, 2010). Environmental signals can 
be transmitted from the mother to the fetus, impacting specific vulnerable tissues in their 
sensitive developmental stage, modulating normal development trajectory, remodeling 
their structure and function and reprogramming the resiliency or susceptibility to diseases 
in postnatal life (Harris and Seckl, 2011). The hypothesis of “developmental 
programming of health and disease” or “fetal origins of adult disease” was put forward to 
4 
elucidate these links between adverse intrauterine environment, fetal growth and 
development, and disease later in life, which proposes that a wide range of environmental 
conditions during embryonic development and early life determine susceptibility to 
disease during adult life (Barker et al., 1993a; de Boo and Harding, 2006; Langley-Evans 
and McMullen, 2010; Seckl, 1998; Wadhwa et al., 2009; Warner and Ozanne, 2010). 
These programming processes may be rely on multiple factors including gestational age, 
duration and mode of exposure and nature of the stressor, and these processes are 
tissue/organ specific (Harris and Seckl, 2011). Genetic traits, epigenetic modifications 
and central stress mediators such as glucocorticoid or catecholamines may underpin such 
phenotypic plasticity. Actually, more and more evidence indicate a close link between the 
adverse fetal environment, mostly manifested as intrauterine growth restriction (IUGR), 
and increased risks of development of hypertension, coronary heart disease, insulin 
resistance, type 2 diabetes, central obesity, hyperlipidaemia, and other neurobehavioral, 
neuropsychological and neuropsychiatric disorders in adulthood (Fig. 1)(Barker et al., 
1993a, 2009; Dudley et al., 2011; Gluckman and Hanson, 2004; Gluckman et al., 2008; 
Harris and Seckl, 2011). 
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Figure 1. Developmental programming of health and disease. Maternal stress impacts 
normal fetal tissues/organs development and increases the risk of development of 
cardiovascular, metabolic syndrome, stroke and various neurobehavioral, 
neuropsychological, neuropsychiatric diseases later in life. HPA, hypothalamic-pituitary-
adrenal. 
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Potential Mechanisms of Fetal Stress-Mediated Programming 
Brain development consists of a series of progressive and regressive events tightly 
regulated by the interaction between cellular and environmental factors. Fetal brain 
development is especially susceptible to environmental perturbations. Prenatal stress 
exposure affects various neurotransmitters, neuromodulators, neurotrophic factors and 
cell adhesion molecules, etc., at specifically susceptible stages to alter neuronal 
development via both acute and chronic effects on cellular behavior and gene expression 
patterns (Levitt, 1998). Aberrant cellular behavior and gene expression confer permanent 
structure remodeling and function reprogramming, which may lead the brain to be more 
vulnerable to later challenges. 
Intrauterine programming of the HPA axis may be one of the key common 
mechanisms underpinning prenatal stress and increased risk of diseases later in life (Fig. 
2). Fetal HPA axis is highly susceptible to programming actions during development. 
Prenatal stress, such as nicotine, cocaine, alcohol, hypoxia, malnutrition and 
glucocorticoid, can directly or indirectly alter the set point of the HPA axis, and enhance 
the activity of the HPA axis in basal and stressful conditions throughout life. 
Glucocorticoid plays the pivotal role in such programming processes, which may be also 
associated with other stress mediators, such as catecholamines (Lee et al., 2008). 
Structures of the limbic system, including hippocampus, hypothalamus, anterior pituitary 
and amygdala, express high levels of GR, constituting the major target of endogenous or 
exogenous glucocorticoid in the brain. These GRs, particularly in hippocampus, exert 
crucial negative feedback regulation on the activity of the HPA axis. Maternal stress or 
synthetic glucocorticoid administration result in high levels of glucocorticoid exposure 
7 
 
 
 
 
 
Figure 2. Mechanisms of developmental programming of neurological diseases. Prenatal 
stress changes normal brain developmental trajectory, alters brain cellular behavior, 
remodels cerebral structure and morphology, reconstructs the HPA axis activity, disturbs 
neurotransmission, and reprograms the vulnerability or resiliency to neurological diseases 
in later life, of which epigenetic modifications of glucocorticoid receptors (GRs) gene 
expression patterns may represent as a common pathway in response to different adverse 
intrauterine stimuli. 11β-HSD2, 11-beta-hydroxysteroid dehydrogenase type-2; HIFs, 
hypoxia inducible factors; HPA, hypothalamic-pituitary-adrenal; nAChR, nicotinic 
acetylcholine receptor. 
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to the fetus, leading to down-regulation of GR in hippocampus and attenuation of 
negative feedback of the HPA axis and enhancement of the HPA axis activity. The 
overall effects of programming allow the body being exposed to sustained elevated 
endogenous glucocorticoid in both basal and stress conditions, resulting in alteration of 
behavior, cognition, learning, memory, emotion and predisposing the individual to a 
variety of cardiovascular and metabolic syndromes in later life (Harris and Seckl, 2011). 
The programming effects of HPA function by prenatal stress may be correlated to the 
exposure’s severity, time, duration, and genetic factors (Harris and Seckl, 2011). 
Glucocorticoid is extraordinary hormone with numerous effects affecting many 
vital organs/systems, including the brain, heart and kidney, etc., and may regulate 
expression patterns of approximately 10% of human genes (Buckingham, 2006). 
Glucocorticoid is essential for life and plays a crucial role in the regulation of growth and 
development, but also is implicated in various pathogenesis. There are two major 
endogenous glucocorticoids, cortisol and corticosterone, both synthesized in mammalian 
species but with different distribution predominance between species. Cortisol is 
predominant in humans while its counterpart corticosterone is principally produced in 
rodents. As the key mediator of stress responses, glucocorticoid is mainly synthesized 
from cholesterol in cells of zona fasciculate of adrenal cortex (Buckingham, 2006). In 
normal conditions, glucocorticoid levels are strictly regulated by negative feedback of 
glucocorticoid on the HPA axis. Disturbance of such feedback regulation loop may result 
in maladaptive impacts on the brain and other organs, contributing to numerous 
pathophysiological changes throughout life. 
Glucocorticoid affects fetal brain development mainly via interaction with its 
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receptors, GR and MR. GR and MR are highly expressed in the developing brain with 
dynamic and complicated ontogeny. During fetal development, GR is present from the 
early embryonic stage in most tissues, but expression of MR is relatively limited and 
presents during later stages of development (Holmes et al., 2003). MR is responsible for 
mediating effects of very low concentrations of glucocorticoid usually in physiological 
conditions, and GR mediates effects of relatively high levels of glucocorticoid when MR 
has been saturated, especially in stress response (Buckingham, 2006). Synthetic 
glucocorticoid is relatively selective for GR. Therefore, GR is likely to be the major 
player in glucocorticoid overexposure. After processes such as ligand binding, 
dimerization and phosphorylation, the glucocorticoid receptor-ligand complex 
translocates into the nucleus and binds to various GREs (glucocorticoid response 
elements) in the gene promoter region, resulting in activation or repression of target gene 
expression. 
Glucocorticoid exerts effects at cellular and molecular levels to affect tissue/organ 
growth and differentiation. During fetal development, high levels of glucocorticoid 
exposure change the expression patterns of various receptors, enzymes, ion channels and 
transporters in most of cell types as well as alteration of various growth factors, 
cytoarchitecture proteins, binding proteins and other essential components of the 
intracellular signaling pathways (Fowden and Forhead, 2004). Such changes significantly 
impact the basal cellular functions and their responses to numerous stimuli, contributing 
to alteration of cell size, number, proliferation rate and terminal differentiation. 
Indirectly, glucocorticoid can also affect tissue proliferation and differentiation via 
altering cellular secretion of proteins, hormones, growth factors and metabolites, which 
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can greatly amplify its programming effects on fetal development (Fowden and Forhead, 
2004). At the molecular level, glucocorticoid regulates target gene transcription, mRNA 
stability, translation/post-translation modifications, etc., which may be mediated by 
directly controlling via GREs in promoter regions of responsive genes or indirectly via 
other transcription factors or glucocorticoid dependent hormones (Fowden and Forhead, 
2004). All of these changes induced by glucocorticoid will confer an integration of 
function at the system level, suggesting that glucocorticoid-mediated programming may 
result in dynamic, multifaceted, co-ordinated and interdependent changes in different 
tissues (Fowden and Forhead, 2004). 
Sufficient glucocorticoid is vital for normal maturation in most regions of the 
developing CNS. However, during vulnerable stages of development, inappropriate levels 
of glucocorticoid may remodel developmental trajectories of specific brain structures and 
alter corresponding functions accompanied by long-lasting adverse consequences, 
notably disturbance of behavior, cognition and disease susceptibility in later life (Harris 
and Seckl, 2011; Seckl and Meaney, 2004). For example, prenatal glucocorticoid 
administration reduces brain weight at birth, delays myelination of the corpus callosum, 
retards astrocyte and vasculature maturation in sheep, and decreases cortex convolutions 
index and surface area in humans (Antonow-Schlorke et al., 2009; Modi et al., 2001). 
Prenatal stress can also diminish dendritic spine density in the anterior cingulated gyrus 
and orbitofrontal cortex in rats (Murmu et al., 2006). Studies in both humans and animals 
have revealed that hippocampus is a highly vulnerable structure particularly sensitive to 
prenatal glucocorticoid exposure, leading to variable memory and behavior deficits. For 
example, prenatal stress in rats can reduce synaptic spine density in hippocampus, which 
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is associated with impairment of reversal learning (Hayashi et al., 1998). Betamethasone 
administration in fetal baboons inhibits neurogenesis and impairs neuronal plasticity via 
downregulation of critical proteins such as cytoskeletal microtubule associated proteins 
and synaptophysin, resulting in cognition deficits (Antonow-Schlorke et al., 2003). In 
addition, antenatal administration of dexamethasone results in neuronal degeneration in 
the hippocampus subfields and reduces the hippocampus volume in a dose-dependent 
manner (Uno et al., 1990). It seems that chronic low levels of glucocorticoid exposure 
may be more deleterious than its short, sharp impact on fetal brain development (Harris 
and Seckl, 2011). Thus, the alteration of hippocampus structure and function may offer a 
plausible neuroanatomical basis for the programming effects of glucocorticoid on 
cognitive ability, behavior and the risk of psychological and psychiatric disorders in later 
life. 
Long-term prenatal glucocorticoid exposure may permanently alter the “set point” 
and sensitivity of endocrine axis, such as the somatotrophic and hypothalamic-pituitary-
adrenal axes (Fowden and Forhead, 2004; Meaney et al., 2007). The HPA axis is an 
important programming target in the brain. It is strictly controlled by a negative-feedback 
mechanism in which glucocorticoid from peripheral adrenal cortex interacts with GR in 
hippocampus, hypothalamus and pituitary to modulate its final level and activity of HPA 
axis in stress. Maternal malnutrition, inhibition of 11β- HSD2 and other prenatal stress 
may reduce tissue-specific expression of GR, particularly in hippocampus and impair the 
negative feedback regulation of glucocorticoid, thus altering the “set point” of the HPA 
axis (Harris and Seckl, 2011; Meaney et al., 2007; Seckl and Meaney, 2004). A large 
variety of animal studies have shown prenatal glucocorticoid exposure permanently 
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increases basal corticosterone/cortisol levels in plasma and enhances the activity of HPA 
axis in adult rats, sheep, guinea pigs and primates (Hawkins et al., 2000; Levitt et al., 
1996; Seckl and Meaney, 2004; Uno et al., 1994). Such changes are dependent on 
gestational age of exposure and also show sex-specific features. Prenatal dexamethasone 
exposure also stimulates CRH expression in the paraventricular nucleus of hypothalamus 
(PVN) and in central nucleus of the amygdala, increasing corticosterone and ACTH 
levels in rat offspring (Levitt et al., 1996). Additionally, prenatal stress may heighten the 
vulnerability of CRH neuron in PVN and also program the development of the HPA axis 
(Tobe et al., 2005). HPA programming may be a common pathway shared by other 
prenatal challenges. Furthermore, prenatal glucocorticoid exposure may have effects 
beyond the CNS and elevate 11β-HSD1 levels in hepatic, visceral adipose tissues, which 
regenerates more active glucocorticoid from its inactive metabolites and further enhances 
adverse effects of glucocorticoid on the developing brain (Cleasby et al., 2003; Nyirenda 
et al., 2009). Given its wide spectrum of physiological and pathophysiological functions, 
it is predictable that chronic excess of glucocorticoid during fetal development and 
overactivity of the HPA axis may increase risks of development of hypertension, 
hyperglycemia, obesity, other metabocardiovascular syndrome, stroke, cognitive 
impairment, affective and other neuropsychiatric disorders in later life, similar to what is 
expected in Cushing’s syndrome (Harris and Seckl, 2011). 
Excessive glucocorticoid exposure may also lead to reprogramming of offspring 
behavior in postnatal life. Glucocorticoid can reprogram expression patterns of several 
key molecules implicated in the regulation of neuronal development, HPA axis and other 
higher cerebral functions (Drake et al., 2007). For example, prenatal glucocorticoid 
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exposure increases CRH and GR expression in the amygdala, a central structure 
mediating emotional response such as fear and anxiety (Welberg et al., 2000, 2001). 
Through elevated CRH and GR, amygdala may positively drive the HPA axis activity, 
which has been supported by transgenic study in mice (Tronche et al., 1999). Prenatal 
glucocorticoid exposure can also influence the development of dopaminergic system, 
contributing to the development of schizoaffective, attention-deficit hyperactivity, 
extrapyramidal disorders and drug addiction (Drake et al., 2007). Some studies also 
suggest that prenatal dexamethasone treatment may enhance vulnerability of cholinergic 
neurons to toxic challenges in later life (Diaz et al., 1995). Human studies have revealed 
the correlation between stressful events during the second trimester of pregnancy and 
incidence of schizophrenia. Of importance, such programming effects are also time-
dependent (Koenig et al., 2002). 
Given its deep involvement in various acute and chronic stress responses, it is 
easy to assume the critical position of catecholamines in programming of fetal 
development by prenatal stress. However, up to now, only a few studies are available to 
indicate the effects of catecholamines (norepinephrine and epinephrine) in fetal stress-
mediated programming of the developing brain. Predictably, prenatal stress can evoke 
enhanced maternal release of norepinephrine via activation of the sympathetic-
adrenalmedullary system, resulting in significant maternal vasoconstriction and/or 
disturbance of maternal cardiovascular function. This will lead to compromised delivery 
of oxygen and nutrients to the fetus and exaggerate adverse effects of other stress stimuli 
on the fetus. More importantly, Sarkar et al. (2001) reported that both norepinephrine and 
epinephrine rapidly repressed 11β-HSD2 mRNA expression in early and late gestational 
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human trophoblast cell lines, which might increase exposure levels of glucocorticoid to 
the fetus in uterus. The downregulation of 11β-HSD2 by catecholamines is mainly 
mediated by activation of α1 and α2 adrenoreceptors and is not dependent on β-adrenergic 
stimulation. However, no similar studies in vivo have been reported yet. There are studies 
implying that catecholamines may exert programming effects on the HPA axis in 
offspring of a fetal ethanol exposure model (Lee et al., 2008). However, most of these 
studies only confer indirect evidence of programming effects of catecholamines. Notably, 
some studies have indicated that maternal catecholamines can cross the placenta, and 
catecholamines are released by the fetus of later stage in stress (Morgan et al., 1972; 
Thomas et al., 1995), suggesting it is plausible that catecholamines may exert direct 
programming effects on fetal brain and other organ development via interaction with their 
specific regionally expressed α and/or β adrenoceptors. Indeed, a recent study in pregnant 
rats demonstrated a key role of increased norepinephrine in nicotine-mediated promoter 
methylation and PKCƐ gene repression in the developing heart and its sustained effect on 
heightened cardiac vulnerability to ischemic and reperfusion injury in adult offspring 
(Lawrence et al., 2011). 
 
Perinatal Nicotine Exposure and Neurological Diseases 
Although the negative effects of cigarette smoking on the development of the 
fetus and the newborn are well-known, it is estimated approximately 22% of mothers and 
45% of fathers continue to smoke during the time of their children’s birth (Nelson and 
Taylor, 2001). Recent studies revealed there are 250 million female smokers around the 
world and over 700,000 children born with exposure to cigarette smoking each year in 
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the United States (Pauly and Slotkin, 2008). Thus, cigarette smoking may represent the 
single largest modifiable neuropharmacological exposure for the fetus and newborn 
(Wickstrom, 2007). Currently, nicotine replacement therapy (NRT) is recommended by 
some obstetricians to help women to quit smoking during pregnancy although there are 
serious concerns about its effectiviness and safety to the mother and fetus (Pauly and 
Slotkin, 2008; Wickstrom, 2007). 
Tobacco contains more than 4000 chemicals, including carbon monoxide, 
cyanide, etc., of which nicotine is the major compound with neurotoxicity (Dwyer et al., 
2009). Nicotine can easily cross the placental barrier and concentrate in fetal circulation, 
brain, amniotic fluid and even breast milk during lactation (Wickstrom, 2007). Large 
amount of nicotine may induce poor nutritional status of mothers via its anorexigenic 
effect and compromise blood flow to the placenta through enhanced release of 
catecholamine from adrenals and sympathetic nerve terminals, which may also contribute 
to chronic placenta insufficiency. More importantly, nicotine can directly affect fetal 
developmental patterns through inappropriate activation of nicotinic acetylcholine 
receptors (nAChRs) and triggering the release of acetylcholine. The most abundant 
subtypes of nAChR in vertebrate brain are α4β2 and α7, of which α7 is highly expressed 
in the immature brain and implicated in the response to brain injury and inflammation 
and participates in regulating the rate of apoptosis (Pauly and Slotkin, 2008). 
Acetylcholine acts as a neurotrophic factor in brain development and is involved in cell 
proliferation, cell differentiation, survival, apoptosis, neuritic outgrowth, neuronal 
migration, synaptogenesis, and establishment of neuronal circuitry and modulation of 
other neurotransmitters releasing. Inappropriate premature stimulation of nAChRs during 
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fetal development may disrupt normal prescheduled program of time and/or intensity of 
these neurotrophic effects and induce abnormal brain development with long-term 
consequences. 
Ample human studies have revealed nicotine exposure during pregnancy is 
associated with a spectrum of adverse fetal and obstetrical outcomes: spontaneous 
abortion, placenta previa, placental abruption, preterm birth, stillbirth, fetal growth 
restriction, low birth weight, and, more severely, sudden infant death syndrome (SIDS) 
(Archer, 2011; Bruin et al., 2010; Eppolito and Smith, 2006; Slotkin, 1998). 
Epidemiological, clinical and experimental studies indicate that adverse effects of 
perinatal nicotine exposure are far beyond the pregnancy outcomes and neonatal 
morbidity or mortality. Long-term poor neurodevelopmental consequences of perinatal 
nicotine exposure constitute the greatest impact on society. A large amount of evidence 
suggests that nicotine plays a key role in mediation of long-term developmental deficits 
resulting from maternal smoking. Except for acetylcholine, directly or indirectly, nicotine 
can also affect a multitude of neurotransmitters’ synthesis, release, reuptake and turnover; 
modulating neural proliferation, differentiation, migration and apoptosis, etc.; altering 
brain structure, organization and morphology; disrupting normal brain development, 
which finally contribute to heightened vulnerability to various neurobehavioral, 
neuropsychological and neuropsychiatric disorders in postnatal life (Bruin et al., 2010; 
Dwyer et al., 2008, 2009; Ernst et al., 2001; Pauly and Slotkin, 2008; Wickstrom, 2007). 
Growing epidemiological studies have revealed that prenatal nicotine exposure is 
associated with various levels of motor and sensory deficits, high incidence of 
externalizing behavioral problems (such as oppositional, aggressive, overactive), 
17 
increased risk of attention-deficit/hyperactivity disorder (ADHD) and conduct disorder 
(CD), cognitive function impairment in memory, attention and learning, and the risk for 
developing drug dependence (e.g., nicotine, cocaine) (Eppolito and Smith, 2006; Ernst et 
al., 2001; Wickstrom, 2007). Consistently, animal studies with prenatal nicotine exposure 
also demonstrate similar presentations including hyperactivity, cognitive and 
somatosensory impairment, exaggerated anxiety, neurochemical imbalance, nicotine self-
administration, reduction of neural cell survival and aberrant synaptogenesis (Dwyer et 
al., 2008, 2009; Eppolito and Smith, 2006; Levitt, 1998). These detrimental brain effects 
can also be induced without apparent birth weight reduction, a crude marker of poor 
intrauterine environment, implying the threshold of brain damage by nicotine is much 
lower than that of inducing IUGR (Slotkin, 1998). It is presumable that perinatal nicotine 
exposure may also be associated with pathogenesis of cerebral ischemia, such as neonatal 
HIE, in offspring.  
Another problem deserving concern is the NRT during pregnancy. Recently, the 
NRT is widely accepted and recommended to pregnant smokers although there is a lack 
of convincing solid evidence for its efficacy and safety. Pharmacologically, the plasma 
half-life of nicotine is about 2 h (Wickstrom, 2007). However, nicotine is metabolized 
more quickly during pregnancy, which indicates that higher doses of NRT may be needed 
to attain an effect for cessation of smoking (Wickstrom, 2007). In addition, most 
formulations of NRT deliver nicotine continuously compared to episodic smoking in 
smokers. The total exposure dosage of nicotine by NRT may actually exceed those of 
pregnant women with mild or moderate cigarette smoking (Wickstrom et al., 2002). 
Furthermore, given the fact of lower threshold for altering brain development by nicotine, 
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more extensive studies should be conducted to justify the efficacy and safety of NRT to 
the fetus before its continued application in pregnancy (Pauly and Slotkin, 2008; 
Wickstrom, 2007). 
 
Hypoxic Ischemic Encephalopathy (HIE) 
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of major causes of acute 
mortality as well as chronic neurological disability in newborns (Chen et al., 2009b; 
Vannucci, 2000). Severe HIE disrupts normal brain development, leading to a wide 
variety of neurodevelopmental deficits presented as various motor and sensory 
abnormality, learning disability, mental retardation and seizure attacks (Vannucci, 1990; 
Vexler and Ferriero, 2001). The incidence of asphyxia is approximately 20% in full-term 
infants and up to 60% in premature infants with low birth weight, of which 20 - 50% 
asphyxiated infants showing HIE symptoms and signs will die and up to 25% of 
survivors demonstrate permanent neurological deficits such as cerebral palsy, mental 
retardation, learning disability and epilepsy (Perlman, 2006; Vannucci, 2000). 
Compromised cerebral blood flow (CBF) is the dominant pathogenetic 
mechanism for neuropathophysiology due to hypoxia-ischemia, which may arise from 
acute reduced materno/feto-placental blood flow or from chronically compromised fetal 
oxygen and energy supply (Perlman, 2006; Terzidou and Bennett, 2001). The resulting 
patterns of HIE injury consist of periventricular white matter lesions in preterm newborn; 
corticosubcortical lesions, particularly in the sensomotor cortex, parasagittal region, and 
deep gray matter lesions of basal ganglia and thalamus in near-term and term newborns. 
Such patterns of injury are associated with brain maturation stage and nature of hypoxic-
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ischemic injury. The etiology of brain damage secondary to HIE is complicated and 
multifaceted. It is well documented that energy failure due to reduction of CBF and 
oxygen delivery initiates the principal pathways contributing to brain cell death. In acute 
phase, energy depletion (primary energy failure) results in increased neuronal release of 
glutamate and reduced reuptake of glutamate by astrocyte, lactate acidosis, glutamate 
receptor (NMDA) activation, intracellular calcium accumulation, generation of ROS, 
lipid peroxidation, NO formation and neurotoxicity, disruption of cell essential 
components, and immediate or delayed cell death. Typically, about 6 - 48 h later, a 
second phase of injury (secondary energy failure) ensues. During this phase, accumulated 
mitochondrial dysfunction secondary to extended injury from primary insults (calcium 
influx, excitotoxicity, oxygen free radicals or NO nitrosative stress) leads to release of 
various cytotoxic enzymes and pro-apoptotic proteins from mitochondria causing delayed 
cell death (Perlman, 2006; Rees et al., 2008, 2011; Vexler and Ferriero, 2001). Evidence 
suggests that some circulatory and endogenous inflammatory cells/mediators may also 
contribute to such ongoing brain injury (Palmer, 1995; Perlman, 2006).  
Of importance, compared with the adult brain, the neonatal brain shows some 
differences in physiological structure organization, ontogeny, function, cellular 
composition and signaling pathway related to gene and protein expression, demonstrating 
more sensitive and plastic features to challenges (Chen et al., 2009b). Such features 
determine that its response to brain injury is also significantly different from the adult 
brain, resulting in distinct acute and chronic neurological consequences, which deserves a 
careful consideration in experimental and clinical studies. For example, the neonatal 
brain shows more permeable immature blood-brain barrier (BBB) that allows readily 
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cross of various solutes and small insoluble molecules in blood (Chen et al., 2009b). The 
major responses to injury and cell death mechanisms are different in the neonatal brain, 
favoring more apoptotic features (Vexler and Ferriero, 2001). Additionally, the response 
to the treatment in the neonatal brain may be also different from that in the adult brain. In 
general, compared with the adult brain, the neonatal brain is more resistant to HI damage 
(Vannucci and Hagberg, 2004).  
Up to now, no universally definite effective therapy is available to intervene with 
this severe neonatal encephalopathy. The only accepted therapy for HIE in clinical 
practice is moderate hypothermia utilized at earlier phase. A recent meta-analysis of 10 
randomized controlled trials confirmed the neuroprotective effects of moderate 
hypothermia administered within 6 h after birth for full-term newborns with mild or 
moderate HIE, showing reduced mortality and neurological deficits at 18 months of age 
(Edwards et al., 2010; Rees et al., 2011). However, it does not improve mortality and 
neurological outcomes in neonates with severe HI brain injury and is contraindicated in 
pre-term neonates. Furthermore, the narrow administration time window also greatly 
restricts its clinical application. Other intervention strategies, such as application of 
excitatory amino acid antagonists, oxygen free radical inhibitors and scavengers, 
inhibition of nitric oxide formation, blockade of apoptosis cascades, application of 
growth factors and neurosteroids, are either still in the experimental stage or in early, 
ongoing, small scale clinical studies or have already failed in clinical trials, showing the 
lack of solid evidence to justify their extensive application (Perlman, 2006; Rees et al., 
2011). 
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AT1R and AT2R in Neurological Diseases 
It is well accepted that RAS is both a circulating and tissue/organ specific 
hormonal system implicated in various physiological and pathophysiological processes 
via the major peptide angiotensin II (Ang II) stimulating its specific AT1R and AT2R, 
which demonstrate opposite effects in many conditions (Sokol et al., 2004; Dasgupta and 
Zhang, 2011; Shi et al., 2010). Both AT1R and AT2R are present in the brain with 
different expression patterns and signaling pathways during different developmental 
stages. Clinical trials and experimental studies have indicated that RAS plays an 
important role in the development and progression of cerebrovascular diseases, but most 
of these studies were conducted in the mature brains. For example, clinical trials such as 
LIFE and MOSES have demonstrated that chronic blockade of RAS can offer 
neuroprotection with the prevention of first or recurrent stroke in high-risk populations, 
independent of its blood pressure-lowering effects (Lindholm et al., 2002; Schrader et al., 
2005). Numerous studies have revealed that AT1R antagonists exhibit anti-apoptotic, 
anti-inflammatory, anti-oxidant effects and improve cerebral perfusion, demonstrating 
vascular-dependent and -independent neuroprotection in acute stroke (Ando et al., 2004; 
Dai et al., 1999; Lou et al., 2004; Zhou et al., 2005). Less is known about the role of 
AT2R in neurological pathophysiology. Emerging evidence indicates that AT2R also 
confers beneficial effects in a variety of pathologies including various neurological 
disorders. Some studies reported that AT2R was up-regulated in stroke, particularly in the 
ischemic area of the brain, implying its potential role in neuroprotection (Mogi et al., 
2006). Increased activation of AT2R may be responsible for some neuroprotective effects 
of AT1R antagonism (Li et al., 2005). In vitro stimulation of AT2R promotes intense 
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neurite outgrowth, which can be antagonized by PD123319 (Laflamme et al., 1996). 
Moreover, McCarthy et al. (2009) demonstrated centrally direct stimulation of AT2R with 
CGP42112 conferred a neuroprotective role in a conscious rat model of stroke, which 
was beyond blood pressure regulation. The underlying mechanisms of AT2R in 
neuroprotection remain to be elucidated. Some studies indicate that it may be related to 
its complicated interaction with AT1R in apoptotic modulation, neuronal regeneration and 
vasodilation in ischemic regions following stroke (Jones et al., 2008; Saavedra et al., 
2006).  
Stressful stimuli in pre- or perinatal developmental stages may reprogram the 
expression patterns of AT1R and AT2R in vital organs such as the heart, vasculature, 
kidney and brain, contributing to later pathologies. Such programming effects may be 
glucocorticoids dependent and sometimes with sex diversity and involve complex 
epigenetic mechanisms. For example, nicotine exposure alters expression patterns of 
AT1R and AT2R in the kidney and vessels, and enhances vascular response to 
vasoconstrictors, which maybe contribute to development of hypertension in adulthood 
(Mao et al., 2009a, b; Xiao et al., 2007, 2008, 2011). In addition, maternal hypoxia during 
gestation can downregulate glucocorticoid receptors in the heart of fetuses and offspring 
and decrease GR binding to the GREs at the AT2R promoter region, resulting in 
increased expression of AT2R and heightened cardiac susceptibility to ischemic-
reperfusion injury in adult offspring (Xue et al., 2011). 
 
Epigenetics in Neurological Diseases 
One of the important adaptive mechanisms that the human body could be evoked 
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to react to some adverse environments is through epigenetic modification of gene 
expression patterns. The fetal developmental stage is the most critical period for the 
human being because in the uterus the fetus could be exposed to inadequate or 
inappropriate environments that could be chemical/nutritional or non-chemical, in which 
different events occur in a way to induce repression or activation of gene transcription via 
epigenetic mechanisms (Chen and Zhang, 2011). These epigenetic changes could be 
associated with conditions or diseases during adulthood (Joss-Moore et al., 2011; Nistala 
et al., 2011; Pinney and Simmons, 2010). 
Environmental factors can have long-lasting effects on gene expression and 
chromatin remodeling.  Dynamic interactions between adverse environmental factors and 
central nervous system underpin the pathogenesis of various neurological disorders 
(Qureshi and Mehler, 2010). Developing brain in fetus and neonate is especially sensitive 
to environmental signals. Epigenetics refers to the heritable changes in gene expression 
without alterations in DNA sequence (Holliday, 1987). Epigenetics reveals molecular and 
cellular processes responsible for modification of gene expression and functional gene 
networks, mainly consisted of DNA methylation; histone code modifications, 
nucleosome remodeling, and higher-order chromatin formation; noncoding RNA; and 
RNA editing, etc.,  which occurs in epigenome throughout life and controls normal 
development, adult homeostasis, aging and responses to environmental stimuli, 
implicating in orchestrating a seemingly infinite of molecular and cellular processes 
essential for higher nervous system functions and evolution innovations (Mehler, 2008; 
Qureshi and Mehler, 2010). Recent studies have revealed the key roles of epigenetic 
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mechanisms in the susceptibility and pathogenesis to some complex diseases, such as 
cancers and neurological diseases (Mehler, 2008). 
Emerging evidence from both human studies and animal experiments indicates 
epigenetic mechanisms deeply implicated in various neurodevelopmental, 
neurodegenerative and neuropsychiatric diseases, including acute stroke (Mehler, 2008; 
Qureshi and Mehler, 2010). Epigenetic mechanisms regulate development, homeostasis 
and plasticity in the CNS which are very sensitive to local and global environmental, 
vascular, systemic and intrinsic CNS factors. In the brain, epigenetic mechanisms are 
critical for brain patterning, neural stem cell maintenance, neurogenesis and gliogenesis, 
synaptic and neural network plasticity and also involved in processing of complicated 
cognitive functions (learning and memory) (Qureshi and Mehler, 2010). It is not 
surprising that epigenetics is involved in the molecular and cellular processes underlying 
various neurological pathogenesis and functional recovery. 
DNA methylation is the most well characterized epigenetic mechanism which 
plays key roles in regulation of gene expression and cellular processes, including 
genomic stability, X chromosome inactivation and genomic imprinting (Robertson, 
2005). Mechanistically, DNA methylation inhibits the process of transcription and 
promotes binding of methyl-CpG-binding domain proteins (MBDs), such as MeCP2, 
which recruit regulatory complexes containing epigenetic factors to methylated genomic 
loci in order to coordinately orchestrate reversible as well as long-term gene silencing 
events. Studies have revealed that MeCP2 is essential for progressive stages of postnatal 
brain development and mature neuronal function, modulates synaptic function and 
plasticity, autonomic responses and sophisticated neurobehavioral functions, regulates 
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axonal pathfinding and neural network development, preferentially involved in a 
spectrum of neurodevelopmental and neuropsychiatric conditions (Mehler, 2008).  In 
general, DNA methylation occurs at CpG rich regions (CpG islands); emerging evidence 
indicates that site-specific CpG methylation at promoter region plays critical roles in gene 
transcription and implicates in various physiological and pathological conditions. DNA 
methyltransferases (DNMTs) mediate DNA methylation by transferring methyl groups 
from S-adenosyl-methionine to cytosine residues in various genomic regions. Members 
of this enzymatic family include DNMT3a and DNMT3b, which stimulate de novo 
methylation involved in dynamic DNA methylation, and DNMT1, which presents high 
levels in the embryonic nervous system and actively maintains the methylation profiles. 
The expression levels and functions of these factors in neural cells are exquisitely 
regulated in an activity-dependent manner throughout development and adult life and are 
responsible for modulating neural subtype specification, maturation, and survival 
(Sharma et al., 2008; Qureshi and Mehler, 2010).  
Aberrant DNA methylation has been linked to a broad spectrum of diseases, such 
as stroke, atherosclerosis, obesity, diabetes, kidney disease, cancer and autoimmunitic 
disorders (Robertson, 2005; Gluckman et al., 2009).  The most intensely studied 
neurological diseases correlated with epigenetic changes is Rett syndrome; patients with 
Rett syndrome present neurodevelopmental defects associated with mutations in the X-
linked gene MECP2, which encodes the methyl CpG binding protein 2, that binds to 
methylated DNA (Amir et al., 1999; Esteller, 2006).  Other mental retardation disorders 
are also linked to the disruption of genes involved in epigenetic mechanisms, such as 
alpha thalassaemia/mental retardation X-linked syndrome, Rubinstein-Taybi syndrome, 
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and Coffin-Lowry syndrome (Urdinguio et al., 2009). Moreover, aberrant DNA 
methylation and histone modifications, at a genome-wide level, have recently been 
considered to be linked to common neurodegenerative disorders such as Alzheimer’s 
disease, Parkinson’s disease, and Huntington’s disease, and in other neurological 
disorders such as multiple sclerosis, epilepsy, and amyotrophic lateral sclerosis 
(Urdinguio et al., 2009).  
Of importance, epigenetic mechanisms are also described in cerebral ischemia 
insults (Qureshi and Mehler, 2010). DNA methylation–mediated regulation of specific 
genes also plays a role in the pathophysiology of stroke. DNA methylation levels are 
increased in ischemic brain tissue following middle cerebral artery occlusion (MCAO) in 
mice and may be responsible for increased cell death (Endres et al., 2000, 2001). Besides, 
DNA methylation inhibitor administration can reduce ischemic injury after MCAO. 
Transgenic mice with lower level of DNMT1 demonstrate smaller infarct size following 
MCAO (Endres et al., 2000, 2001). DNA methylation may make multifaceted effects in 
cerebral ischemia and influences the susceptibility of CNS to various insults (Qureshi and 
Mehler, 2010). All of these findings indicate that dynamic modulation of DNMT 
expression and DNA methylation status represents an important mechanism in regulation 
of cell death or survival in cerebral ischemia, offering us a promising interventional 
target. Interestingly, recent studies indicate that differential DNA methylation profiles 
mediate sex differences in the endogenous neuroprotective response to MCAO. Dramatic 
upregulation of the estrogen receptor α (ERα) is an endogenous response to MCAO that 
attenuates ischemic cell death in young female rats (Wilson and Westberry, 2009). 
Although ERα is primarily expressed during neonatal development, MCAO induces 
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selective demethylation of the ERα gene promoter in females, leading to the increase in 
ERα expression and confers additional protective effects in response to ischemic insults 
(Westberry et al., 2008). 
 Histone code modification represents another important epigenetic process which 
mainly functions at single nucleotide and accounts for modulating chromatin structure. 
The histone code refers to profiles of posttranslational modifications of histone proteins 
(e.g., acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, and 
adenosine diphosphate– ribosylation) that are catalyzed by specific enzymes (e.g., histone 
acetyltransferases and histone deacetylases [HDACs]) (Jenuwein and Allis, 2001). It is 
increasingly recognized that dynamic modulation of chromatin states is associated with 
the molecular mechanisms that mediate neural cell death and protective responses in 
stroke (including excitotoxicity, oxidative stress, inflammation, cell cycle regulation, 
DNA repair, and apoptosis). Abnormal chromatin may be a key feature of necrotic cell 
death and apoptotic cell death, which are both closely associated with neural injury in 
stroke. Although the different roles played by chromatin regulation in the 
pathophysiology of cerebral ischemia are not well characterized, emerging evidence 
suggests that these functions are extremely important and, furthermore, that chromatin-
modifying agents may be neuroprotective (Langley et al., 2009). Study has showed that 
brain tissue subjected to MCAO exhibits significant changes in histone acetylation 
(Faraco et al., 2006). Several preclinical studies have also shown that the administration 
of various HDAC inhibitors in animal models of cerebral ischemia decreases the extent 
of neuronal injury and improves functional outcomes levels (Faraco et al., 2006). In 
addition, histone acetylation also plays a role in the protection of neurons against 
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oxidative stress by indirectly promoting the function of neuroprotective antioxidant 
enzymes (i.e., peroxiredoxins) (Soriano et al., 2009). A recent review has also suggested 
that these agents are generally effective in promoting neuroprotection (Langley et al., 
2009). 
MicroRNAs represent one of the best-characterized subclass of ncRNAs up to 
now. MicroRNAs regulate developmental and homeostatic gene expression programs in a 
highly environmentally responsive manner and are implicated in neural differentiation, 
maintenance, and plasticity (Schratt, 2009). Cerebral ischemia in animal models is 
associated with highly selective and temporally regulated profiles of miRNAs in the 
postischemic brain (Jeyaseelan et al, 2008; Dharap et al., 2009). Differential expression 
patterns of miRNAs in the postischemic brain correlates with differential expression of 
their target mRNAs, many of which may be implicated in transcriptional regulation, ionic 
flux, inflammation, and other stress responses. These results suggest that miRNA 
networks may regulate a spectrum of pathological processes in the postischemic brain. 
For example, MicroRNA-140 is one of the miRNAs that was rapidly upregulated in the 
brain 3 hours after middle cerebral artery occlusion and sustained for 72 hours. One of 
the validated target mRNAs for miRNA-140 encodes stromal cell– derived factor 1, 
which plays an important role in the CNS by mediating neural progenitor cell 
proliferation and migration and tissue repair after cerebral ischemia (Nicolas et al., 2008), 
suggesting miRNA-140, at least in part, implicated in rehabilitating response after brain 
ischemic insult. Another neurological disease most frequently associated with miRNAs is 
fragile X syndrome, which manifests with various severity of a range of cognitive or 
intellectual disabilities and caused by mutations in the FMR1 gene located on the long 
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arm of the X chromosome. FMR1 encodes FMRP, which is an RNA binding protein and 
associated with RISC and with miRNAs themselves (Jin et al., 1998; Kosik, 2006).  
A number of epigenetic agents, such as DNA methylation and HDAC inhibitors, 
have already been evaluated in preclinical and clinical trials (Mehler, 2008). However, 
these therapeutic approaches are still in their infancy. Existing agents usually exert 
relatively nonspecific effects directed towards a restricted number of epigenetic 
processes. Importantly, it provides us with another promising interventional target to 
overcome those complex neurological diseases.   
  
Central Hypothesis 
The central hypothesis of our project is that perinatal nicotine exposure causes 
epigenetic programming of aberrant expression patterns of AT1R and/or AT2R in the 
developing brain, resulting in heightened susceptibility to neonatal hypoxic ischemic 
brain injury. 
 
Significance 
Both human and animal studies have supported the notion of developmental 
origins of adult health and disease. Prenatal stress including nicotine exposure exerts 
great impacts on the fetus during the vulnerable developmental stage at multifaceted 
levels, which may contribute to adverse programming of ischemic-sensitive phenotype in 
the developing brain and heightened vulnerability of neonatal hypoxic-ischemic 
encephalopathy and long-term neurodevelopmental disorders. Cigarette smoking 
represents the single largest modifiable neuropharmacological exposure for the fetus and 
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newborn (Wickstrom, 2007). Nowadays, neonatal hypoxic-ischemic encephalopathy 
(HIE) is still one of major causes of acute mortality as well as chronic neurological 
disability in newborns. Because of current deficiency in potent and effective therapy, the 
prognosis and outcome for most neonatal HIE are less than optimal at the best, which 
makes urgently necessary for further exploration and investigation of pathophysiology 
and underlying mechanisms for the heightened neonatal HIE. Epigenetic modification of 
gene expression patterns provides us with a promising interventional target although it is 
still in its infancy stage. Further studies on the epigenetic regulation of AT1R and AT2R 
gene expression patterns induced by perinatal nicotine exposure in the developing brain 
should provide more insights into mechanisms at the molecular level and may suggest 
new insights of preventable and therapeutic strategies that may finally contribute to the 
treatment of HIE in newborns.   
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Abstract 
Maternal cigarette smoking increases the risk of neonatal morbidity. We tested the 
hypothesis that perinatal nicotine exposure causes heightened brain vulnerability to 
hypoxic–ischemic (HI) injury in neonatal rats through aberrant expression patterns of 
angiotensin II type 1 (AT1R) and type 2 (AT2R) receptors in the developing brain. 
Nicotine was administered to pregnant rats through subcutaneous osmotic minipumps. HI 
brain injury was determined in 10-day-old pups. AT1R and AT2R expression patterns 
were assessed through Western blotting, quantitative polymerase chain reaction, 
immunofluorescence, and confocal imaging. Perinatal nicotine exposure significantly 
increased HI brain infarct size in male, but not female, pups. In fetal brains, nicotine 
caused a decrease in mRNA and protein abundance of AT2R but not AT1R. The 
downregulation of AT2R persisted in brains of male pups, and nicotine treatment resulted 
in a significant increase in methylation of CpG locus 3 bases upstream of TATA-box at 
the AT2R gene promoter. In female brains, there was an increase in AT2R but a decrease 
in AT1R expression. Both AT1R and AT2R expressed in neurons but not in astrocytes in 
the cortex and hippocampus. Central application of AT1R antagonist losartan or AT2R 
antagonist PD123319 increased HI brain infarct size in both male and female pups. In 
male pups, AT2R agonist CGP42112 abrogated nicotine-induced increase in HI brain 
infarction. In females, PD123319 uncovered the nicotine’s effect on HI brain infarction. 
Perinatal nicotine exposure causes epigenetic repression of the AT2R gene in the 
developing brain resulting in heightened brain vulnerability to HI injury in neonatal male 
rats in a sex-dependent manner. 
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Introduction 
Hypoxic–ischemic encephalopathy (HIE) occurs in one to 6 per 1000 term 
newborns and causes severe mortality and long-lasting morbidity, including cerebral 
palsy, seizure, and cognitive retardation in infants and children (Ferrieo, 2004; Verklan, 
2009). Although the underlying mechanisms of heightened brain vulnerability to 
hypoxic–ischemic (HI) injury in newborns remain largely elusive, recent studies suggest 
a possible cause of aberrant brain development due to fetal insults (Jensen, 2006). 
Maternal cigarette smoking is the single most widespread perinatal insult in the world. As 
one of the major components in cigarette smoking, nicotine readily crosses the placenta 
and produces higher nicotine concentrations in the fetal circulation than that experienced 
by the mother (Lambers and Clark, 1996). 
Epidemiological and animal studies have provided evidence linking perinatal 
nicotine exposure and the increased incidence of neurodevelopmental disorders, 
neurobehavioral deficits, impaired cognitive performance, and increased risk of affective 
disorders later in life (Wickstrom, 2007; Pauly and Slotkin, 2008). However, whether and 
to what extent perinatal nicotine exposure adversely affects the brain susceptibility to HI 
injury in newborns remains unknown. The present study tested the hypothesis that 
maternal nicotine administration during gestation results in heightened brain vulnerability 
to HI injury in neonatal rats. Given that the brain renin–angiotensin system plays a vital 
role in the development and progression of cerebrovascular diseases, and both 
angiotensin II type 1 (AT1R) and type 2 (AT2R) receptors are pivotal players in the 
pathogenesis of ischemic brain injury (Sokol et al., 2004; Schrader et al., 2005; Ando et 
al., 2004), we sought to investigate further the role of AT1R and AT2R in the nicotine-
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mediated ischemia-sensitive phenotype of neo-natal brains. We present evidence of a 
novel finding that perinatal nicotine exposure causes epigenetic programming of AT2R 
gene repression in the developing brain resulting in the increased brain susceptibility to 
HI injury in neonatal male rats in a sex-dependent manner and suggest new insights of 
molecular mechanisms linking maternal cigarette smoking to heightened HIE 
vulnerability in newborns. 
 
Materials and Methods 
Experimental Animals 
Pregnant Sprague-Dawley rats were purchased from Charles River Laboratories 
(Portage, MI) and were randomly divided into 2 groups: (1) saline control; and (2) 
nicotine administration through osmotic minipumps (4 μg/kg/min) implanted 
subcutaneously from Day 4 of gestation to Day 10 after birth (Lawrence et al., 2011). On 
Day 21 of pregnancy, some rats were euthanized and fetal (E21) brains were isolated. 
Other rats were allowed to give birth, and further studies were conducted in 10-day-old 
neonatal (P10) pups of both sexes. All procedures and protocols were approved by the 
Institutional Animal Care and Use Committee of Loma Linda University and followed 
the guidelines by the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
 
Brain HI Treatment and Intracerebroventricular Injection 
A modified Rice-Vannucci model was conducted in P10 pups (Vannucci, et al., 
1999). Pups were anesthetized with 2% isoflurane and the right common carotid artery 
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was ligated. After recovery for 1 hour, pups were treated with 8% O2 for 1.5 or 2.5 hours. 
To determine the role of AT1R and AT2R in brain HI injury, AT1R antagonist losartan 
(Merck), AT2R antagonist PD123319 (Sigma-Aldrich), and AT2R selective agonist 
CGP42112 (TOCRIS Bioscience) were administered intracerebroventricularly, 
respectively, before the HI treatment. Pups were anesthetized and fixed on a stereotaxic 
apparatus (Stoelting, Wood Dale, IL). An incision was made on the skull surface and 
bregma was exposed. All agents were injected at a rate of 1 μL/min with a 10 μL syringe 
(Stoelting) on the right hemisphere following the coordinates relative to bregma: 2 mm 
posterior, 1.5 mm lateral, and 3.0 mm below the skull surface (Han and Holtzman, 2000). 
Saline was injected as a control. The injection lasted 2 minutes and the needle was kept 
for additional 5 minutes before its removal. The incision was sutured. 
 
Infarct Size Measurement 
Pups were anesthetized and euthanized 48 hours after the HI treatment. Coronal 
slices of the brain (2 mm thick) were cut and immersed in a 2% solution of 2,3,5- 
triphenyltetrazolium chloride monohydrate (Sigma-Aldrich) for 5 minutes at 37°C and 
then fixed by 10% formaldehyde overnight. Each slice was weighed, photographed 
separately, and the percentage of infarction area for each slice was analyzed by Image J 
software (Version 1.40; National Institutes of Health, Bethesda, MD), corrected by slice 
weight, summed for each brain, and expressed as a percentage of whole brain weight. 
 
Western Immunoblotting 
Brains were homogenized in a lysis buffer containing 150 mmol/L NaCl, 50 
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mmol/L Tris HCl, 10 mmol/L EDTA, 0.1% Tween-20, 1% Triton, 0.1% β-
mercaptoethanol, 0.1 mmol/L phenylmethylsulfonyl fluoride, 5 μg/mL leupeptin, and 5 
μg/mL aprotinin, pH 7.4. Homogenates were centrifuged at 4°C for 10 minutes at 10 000 
g, and supernatants collected. Protein concentrations were determined using a protein 
assay kit (Bio-Rad, Hercules, CA). Samples with equal amounts of protein were loaded 
onto 10% polyacrylamide gel with 0.1% sodium dodecyl sulfate and separated by 
electrophoresis at 100 V for 90 minutes. Proteins were then transferred onto 
nitrocellulose membranes and probed with primary antibodies against AT1R (1:100) and 
AT2R (1:1000; Santa Cruz Biotechnology; Santa Cruz, CA) as described previously (Xue 
et al., 2011). After washing, membranes were incubated with secondary horseradish 
peroxidaseconjugated antibodies. Proteins were visualized with enhanced 
chemiluminescence reagents, and blots were exposed to Hyperfilm. The results were 
analyzed with Kodak ID image analysis software. Band intensities were normalized to 
glyceraldehyde-3-phosphate dehydrogenase.  
 
Real-Time Reverse Transcription–Polymerase Chain Reaction 
RNA was extracted from brains and abundance of AT1aR, AT1bR, and AT2R 
mRNA was determined by real-time reverse transcription– polymerase chain reaction 
using an Icycler Thermal cycler (Bio-Rad, Hercules, CA), as described previously (Xue 
et al., 2011). The primers used were: AT1aR, 5ʼ-ggagaggattcgtggcttgag-3ʼ (forward) and 
5ʼ- ctttctgggagggttgtgtgat-3ʼ (reverse); AT1bR, 5ʼ-atgtctccagtcccctctca-3ʼ (forward) and 
5ʼ-tgacctcccatctccttttg-3ʼ (reverse); and AT2R, 5ʼ- caatctggctgtggctgactt-3ʼ (forward) and 
5ʼ-tgcacatcacaggtccaaaga-3ʼ (reverse). Real-time reverse transcription–polymerase chain 
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reaction was performed in a final volume of 25 μL. Each polymerase chain reaction 
mixture consisted of 600 nmol/L of primers, 33 U of M-MLV reverse transcriptase 
(Promega, Madison, WI), and iQ SYBR Green Supermix (Bio-Rad) containing 0.625 U 
Taq polymerase, 400 μmol/L each of dATP, dCTP, dGTP, and dTTP, 100 mmol/L KCl, 
16.6 mmol/L ammonium sulfate, 40 mmol/L Tris-HCl, 6 mmol/L MgSO4, SYBR Green 
I, 20 nmol/L fluorescing, and stabilizers. The following reverse transcription–polymerase 
chain reaction protocol was used: 42°C for 30 minutes, 95°C for 15 minutes followed by 
40 cycles of 95°C for 20 seconds, 56°C for 1 minute, 72°C for 20 seconds. 
Glyceraldehyde-3-phosphate dehydrogenase was used as an internal reference and serial 
dilutions of the positive control was performed on each plate to create a standard curve. 
Polymerase chain reaction was performed in triplicate, and threshold cycle numbers were 
averaged. 
 
Quantitative Methylation-Specific Polymerase Chain Reaction 
CpG methylation at rat AT2R gene promoter was determined as previously 
described (Lawrence et al., 2011; Pattersen et al., 2010). Briefly, genomic DNA was 
isolated from brains of P10 pups using a GenElute Mammalian Genomic DNA Mini-Prep 
kit (Sigma), denatured with 2 N NaOH at 42°C for 15 minutes, treated with sodium 
bisulfite at 55°C for 16 hours, and purified by EZ DNA Methylation-Gold Kit (Zymo 
Research), as previously described. Bisulfite-treated DNA was used as a template for 
real-time fluorogenic methylation-specific polymerase chain reaction at CpG-52 locus 
(forward primer, 5ʼ-ttttttggaaagttggtaagtgttta-3ʼ; reverse primer for C, 5ʼ-
ctctaatttccttcttatatattca-3ʼ; reverse primer for Cm, 5ʼ- ctctaatttccttcttatatattcg-3ʼ) and 
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CpG+11 locus (forward primer, 5ʼ- gaaggttttttagtggatag- 3ʼ; reverse primer for C, 5ʼ-
aaaaaaaactttcaattctatactca- 3ʼ; reverse primer for Cm, 5ʼ-aaaaaaaactttcaattctatactcg-3ʼ), 
respectively. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal 
reference gene. Real-time methylation-specific polymerase chain reaction was performed 
using the iQ SYBR Green Supermix with iCycler real-time polymerase chain reaction 
system (Bio-Rad). Data are presented as the percent of methylation at the region of 
interest (methylated CpG/methylated CpG + unmethylated CpG×100), as described 
previously (Lawrence et al., 2011; Pattersen et al., 2010). 
 
Immunofluorescence Staining and Confocal Imaging 
Brains were fixed in formalin and processed to obtain 10-μm tissue slides. 
Antigens were retrieved with antigen retrieval buffer (Abcam) after heat-induced 
procedures. The following primary antibodies were used: mouse antineuronal nuclei 
(Millipore); mouse anti glial fibrillary acidic protein (Millipore); rabbit anti-AT1R (Santa 
Cruz); and rabbit anti-AT2R (Santa Cruz). After blocking with 1% bovine serum albumin 
for 2 hours at room temperature and incubation with the primary antibodies at 4°C 
overnight, tissue sections were treated with secondary antibodies raised against mouse 
and rabbit IgG conjugated with fluorescein isothiocyanate and Texas Red (Santa Cruz), 
respectively, for 2 hours at room temperature. After 3 washes, sections were stained with 
Hoechst 33258 (5 μg/mL; Sigma) for 1 minute. The sections were then covered with 
Permount reagent (Fisher) and visualized using the Zeiss LSM 710 confocal microscope, 
as previously described (Xiong et al., 2012). 
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Statistical Analysis 
Data are expressed as mean ± SEM. Experimental number (n) represents fetuses 
and neonates from different dams. Statistical significance (P<0.05) was determined by 
analysis of variance followed by Neuman - Keuls post hoc testing or Student t test, where 
appropriate. 
 
Results 
Nicotine Caused Asymmetrical Growth Restriction in Fetuses and Neonates 
Maternal nicotine administration caused a significant decrease in the body weight, 
but not the brain weight, in E21 fetuses, resulting in a significant increase in the brain to 
body weight ratio (Figure 3A). In P10 pups, both body and brain weight were decreased 
but the brain to body weight ratio remained significantly increased in both sexes (Figure 
3B), suggesting asymmetrical growth restriction in the fetus and neonate in nicotine-
treated animals. 
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Figure 3. Effect of nicotine on body weight, brain weight, and brain to body weight ratio 
in E21 fetuses (A; n = 27–39) and P10 pups (B; n = 9–13). Data are mean ± SEM. 
*P<0.05 versus control group. P10 indicates 10-day-old neonatal. 
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Nicotine Increased Brain Vulnerability to HI Injury in Male Pups 
In control animals, there was no significant difference in HI-induced brain infarct 
size between male and female pups (Figure 4). The nicotine treatment significantly 
exaggerated HI-induced brain infarct size in male, but not female, pups (Figure 4). 
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Figure 4. Effect of nicotine on HI-induced brain infarct size in P10 pups. Data are mean ± 
SEM, n = 4 to 6. *P<0.05 versus control group. HI indicates hypoxia–ischemia; P10, 10-
day-old neonatal. 
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Nicotine Altered Expression Patterns of AT1R and AT2R in Fetal 
and Neonatal Brains 
In E21 fetuses, the nicotine treatment resulted in a significant decrease in brain 
AT2R protein and mRNA abundance (Figure 5A–B). There was no significant effect of 
nicotine on AT1R protein abundance with a significant decrease in AT1aR mRNA but an 
increase in AT1bR mRNA abundance in the fetal brain (Figure 5B). In P10 pups, brain 
AT2R protein and mRNA abundance were significantly decreased in male pups in 
nicotine-treated animals (Figure 5C–D). In contrast, in female pups, nicotine caused a 
significant increase in brain AT2R protein and mRNA abundance (Figure 5C–D). There 
was no significant effect of nicotine on brain AT1R protein, AT1aR, and AT1bR mRNA 
abundance in male pups (Figure 5C–D). However, nicotine induced a significant 
reduction of brain AT1R protein and AT1aR mRNA abundance in female pups (Figure 
5C–D). Immunofluorescence and confocal imaging analyses showed that both AT1R and 
AT2R presented in neurons but not in astrocytes in the cortex (Figure 6) and hippocampus 
(Figure 7) of P10 pups. It appeared that nicotine treatment increased astrocyte numbers in 
both cortex and hippocampus (Figure 8). 
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Figure 5. Effect of nicotine on protein and mRNA abundance of AT1R and AT2R in E21 
fetal (A–B) and P10 pup (C–D) brains. Data are mean ± SEM, n = 4 to 6. *P<0.05 versus 
control group. AT1R indicates angiotensin II type 1 receptor; AT2R, angiotensin II type 2 
receptor; P10, 10-day-old neonatal.  
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Figure 6. Immunoreactivity of AT1R and AT2R in the cortex of P10 pup brains. NeuN is 
visualized by FITC (green). AT1R and AT2R are visualized with Texas Red (red). Arrows 
show the peri-nuclear location of AT1R and AT2R. Scale bar: 50 μm. Representative 
immunofluorescence confocal images of samples from 3 animals in each group are 
shown. 
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Figure 7. Immunoreactivity of AT1R and AT2R in the hippocampus of P10 pup brains. 
NeuN is visualized by FITC (green). AT1R and AT2R are visualized with Texas Red 
(red). Arrows show the peri-nuclear location of AT1R and AT2R. Scale bar: 50 μm. 
Representative immunofluorescence confocal images of samples from 3 animals in each 
group are shown. 
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Figure 8. Immunostaining of astrocytes with GFAP in the cortex (A) and hippocampus 
(B) of P10 pup brains. Scale bar: 50 μm. Representative immunofluorescence confocal 
images of samples from 3 animals in each group are shown.  
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AT1R and AT2R Protected Neonatal Rat Brains from HI Injury 
To determine the functional significance of altered AT1R and AT2R expression 
patterns in nicotine-induced, heightened brain vulnerability to HI injury in neonates, we 
first evaluated the role of AT1R and AT2R in the pathogenesis of HI brain injury in pups 
through intracerebroventricular (ICV) injection of AT1R or AT2R antagonists. Compared 
with the saline control, ICV of either losartan (Figure 9A) or PD123319 (Figure 9B) 
significantly increased brain infarct size in both male and female pups, suggesting that 
both AT1R and AT2R may be implicated in the pathogenesis of HI brain injury and 
confer neuroprotective properties in neonatal rat brains. 
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Figure 9. Effect of losartan (A) and PD123319 (B) on HI-induced brain infarct size in 
P10 pups. Data are mean ± SEM, n = 4 to 6. *P<0.05 versus control group. HI indicates 
hypoxia–ischemia; P10, 10-day-old neonatal. 
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AT2R Played a Key Role in Nicotine-Induced, Heightened Brain 
Vulnerability to HI Injury in Pups 
To demonstrate the cause and effect relation between nicotine-induced 
downregulation of brain AT2R and heightened brain vulnerability to HI injury in male 
pups, a selective AT2R agonist, CGP42112, was administered in male pups that had been 
treated with nicotine or saline control. As shown in Figure 10A, ICV administration of 
CGP42112 (3 μg) reversed the effect of nicotine and abrogated the difference in HI-
induced brain infarct size between saline control and nicotine-treated male pups. The key 
role of brain AT2R in nicotine-induced heightened brain vulnerability to HI injury in 
neonatal rats was further tested in female pups with ICV administration of PD123319. As 
shown in Figure 10B, in the absence of PD123319, the nicotine treatment had no 
significant effect on brain HI injury in female pups. However, in the presence of 
PD123319 (5 μg), the effect of nicotine was uncovered and HI-induced brain infarct size 
was significantly increased in nicotine-treated, as compared with saline control, female 
pups (Figure 10B). 
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Figure 10. Effect of CGP42112 (CGP) in male P10 pups (A) and PD123319 (PD) in 
female P10 pups (B) on nicotine-induced changes in brain HI injury. Data are mean ± 
SEM, n = 4 to 8. *P<0.05 versus control group. P10 indicates 10-day-old neonatal; HI, 
hypoxia–ischemia. 
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Nicotine Treatment Increased Methylation of CpG-52 Locus at 
AT2R Promoter 
Recently, we have demonstrated that rat AT2R promoter has a TATA element at -
48 from transcription start site, and deletion of the TATA element significantly decreases 
the promoter activity (Xue et al., 2011). Two CpG loci were identified at the AT2R 
promoter; one was located 3 bases upstream of TATA-box (CpG-52) and the other one 11 
bases downstream of transcription start site (CpG+11). The previous study showed that 
increased methylation at CpG locus 3 bases upstream of TATA-box inhibited the binding 
of the TATA-box binding protein and decreased promoter activity (Kitazawa and 
Kitazawa, 2007). As shown in Figure 11, nicotine treatment caused a significant increase 
in methylation of CpG-52 locus in male but not female pup brains, whereas methylation of 
CpG+11 locus was not significantly affected. 
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Figure 11. Effect of nicotine on methylation of CpG loci at AT2R promoter in P10 pup 
brains. Data are mean ± SEM, n = 5 to 10. *P<0.05 versus control group. AT2R indicates 
angiotensin II type 2 receptor; P10, 10-day-old neonatal. 
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Discussion 
The new findings of the present study are: (1) perinatal nicotine exposure 
significantly increases brain vulnerability to HI injury in male rat pups, but not in female 
pups; (2) this heightened vulnerability is associated with sex-specific reprogramming of 
AT1R and AT2R expression patterns in the developing brain; (3) both AT1R and AT2R 
are implicated in the pathogenesis of HI brain injury and exhibit the neuroprotective 
effect in neonatal brains; (4) downregulation of AT2R in the developing brain plays a 
causal role in nicotine-induced, heightened brain vulnerability to HI injury in neonatal 
rats; and (5) increased methylation of CpG locus 3 bases upstream of TATA-box at the 
AT2R promoter is a mechanism of nicotine-mediated AT2R gene repression. 
The present finding that perinatal nicotine exposure increased brain HI injury in 
neonates is novel and suggests a risk factor of maternal cigarette smoking in heightened 
brain HIE vulnerability in newborns. The nicotine dose used in the present study resulted 
in blood nicotine concentrations similar to those found in humans who smoke or use 
nicotine gum and patch (Lambers and Clark, 1996; Slotkin, 1998). Nicotine readily 
crosses the placenta into the fetal circulation, resulting in fetal nicotine concentrations 
being 15% higher than maternal levels (Koren, 1995). It is unclear at present whether 
observed effects are caused by vascular effects or direct neuronal effects of nicotine. 
Although it may be technically challenging in measuring cerebral blood flow in neonatal 
rats, possible alterations in cerebral blood flow caused by nicotine treatment deserve 
further investigation. 
The Rice-Vannucci model of unilateral common carotid artery ligation followed 
by 2.5 to 3 hours of 8% oxygen treatment produces extensive brain damage in neonatal 
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rats and is widely used in studies of potential therapeutic intervention. However, few 
studies examined the brain susceptibility to mild HI injury in neonates, which may 
present only subtle differences and require more sophisticated experimental procedures. 
In the present study, a shorter treatment period of pups with 8% oxygen for 1.5 hours 
produced mild brain damage of approximately 10% infarction in the ipsilateral 
hemisphere. This mild and clinically relevant brain HI injury was significantly increased 
by >2-fold in nicotine-treated male pups. However, the longer period of hypoxic 
treatment with greater brain damage in the model masked the effect of nicotine, 
suggesting a critical importance of appropriate model in investigating subtle changes of 
heightened brain vulnerability of HIE in newborns. 
The growth restriction found in nicotine-treated animals presents a possible link 
between perinatal nicotine exposure and enhanced brain HI injury in pups given that 
intrauterine growth restriction is a risk factor of neonatal encephalopathy (Yager and 
Ashwal, 2009). Fetal hypoxia may be another possible factor enhancing the nicotine-
mediated effects. Although intermittent injections of nicotine to the mother may produce 
episodic fetal hypoxia and a decrease in cerebral perfusion with a reduced fetal brain 
weight (Arbeille et al., 1992: Onal et al., 2004; Mao et al., 2008), these effects were not 
observed in continuous low-level infusion of nicotine through a minipump (Slotkin, 
1998). 
The finding that ICV application of both AT1R and AT2R antagonists enhanced 
the severity of brain HI injury is intriguing and suggests that both AT1R and AT2R are 
neuroprotective in the setting of neonatal HI brain injury. Both AT1R and AT2R present 
in the brain with specific developmental and spatial expression patterns. In adult brains, 
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the AT1R predominates, whereas fetal brains express high levels of AT2R that decrease 
during the postnatal development (Millan et al., 1991). The present study demonstrated 
that both AT1R and AT2R expressed exclusively in neurons in both cortex and 
hippocampus in neonatal rat brains, whereas AT1R expressed predominantly in astrocytes 
in adult brains (Li et al., 2005). The neuroprotective effect of AT2R demonstrated in the 
present study is consistent with previous findings (Li et al., 2005; Iwai et al., 2004; 
McCarthy et al., 2009). In contrast, the present finding of a neuroprotective effect of 
AT1R in neonatal brains is somewhat surprising given that AT1R antagonists have been 
shown to exhibit neuroprotection in adult rat brains (Ando et al., 2004; Dai et al., 1999; 
Lou et al., 2004; Zhou et al., 2005). These findings highlight the important differences 
between immature and mature brains in AT1Rmediated responses. It has been shown that 
apoptotic cell death is more prominent in immature brains to HI insult, but necrotic cell 
death is more common in adult brains in response to acute insults such as HI or 
excitotoxicity (Rothman and Olney, 1986; Sidhu et al., 1997). Although long-term and 
systemic administration of AT1R antagonists often showed neuroprotective effects of the 
brain through multiple systemic effects, the acute and local direct effects of AT1R 
antagonists in modulating brain HI injury are indeed less clear and may be quite different 
from those seen in the long-term and systemic effects. Indeed, similar to the present 
finding, the previous studies demonstrated a direct adverse effect of local administration 
of AT1R antagonists in the setting of acute ischemic injury in the heart (Xue et al., 2011; 
Ford et al., 1996) despite well-documented protective effects of long-term and systemic 
administration of AT1R blockers in preventing the deleterious consequences of ischemia 
and reperfusion injury and reducing cardiac remodeling. 
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Of importance, the present study demonstrated that perinatal nicotine exposure-
mediated, heightened brain vulnerability to HI injury in male pups was associated with a 
significant decrease in brain AT2R expression. Additionally, the ICV administration of 
the AT2R agonist CGP42112 abrogated nicotine’s effect. It has been demonstrated that 
direct stimulation of AT2R in the brain with CGP42112 confers neuroprotective effects in 
a conscious rat model of stroke, which is beyond blood pressure regulation (McCarthy et 
al., 2009). These results provide evidence of a causal role of AT2R downregulation in the 
nicotine-induced increase in brain HI injury in the pups. Our recent study has revealed 
that rat AT2R promoter has a TATA element at -48 from transcription start site and 
deletion of the TATA-box significantly decreases the promoter activity (Xue et al., 
2011). The finding that nicotine treatment significantly increased methylation of CpG-52 
locus 3 bases upstream of TATA-box at the AT2R promoter in male pup brains is 
intriguing and suggests an important mechanism of site-specific CpG methylation in 
epigenetic repression of AT2R gene in the developing brain. It has been demonstrated that 
increased methylation at CpG locus 3 bases upstream of TATA-box inhibits the binding 
of the TATA-box binding protein and decreases receptor activator of nuclear factor-κB 
ligand gene promoter activity (Kitazawa and Kitazawa, 2007). Unlike CpG-52 locus, 
methylation of CpG+11 locus was not significantly altered, suggesting its minimal role in 
programming of AT2R gene expression patterns in the brain. Perinatal nicotine-mediated 
increase in sequence-specific CpG methylation has recently been demonstrated in the 
Egr-1 binding site at PKCƐ promoter in the developing heart, which causes PKCƐ gene 
repression (Lawrence et al., 2011). Interestingly, nicotine had no significant effect on 
methylation of CpG-52 locus in female pup brains, demonstrating a sex-specific effect at a 
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developmental period that sex hormonal influences are minimal. This suggests there are 
transcriptional distinctions that are wired in males and females long before sex steroids 
are involved. Similar findings of sex-specific CpG methylation and epigenetic repression 
of the PKCƐ gene were obtained in male fetal rat hearts in response to hypoxia, in which 
the greater expression of estrogen receptors in female fetuses may convey a protection in 
stress-mediated epigenetic modifications (Patterson et al., 2010). In the present study, the 
mechanism of increased AT2R expression in female pup brains is not clear at present. A 
possible mechanism is that stress-mediated downregulation of glucocorticoid receptors 
may contribute to the upregulation of AT2R, as shown recently in fetal rat hearts (Xue et 
al., 2011). Additionally, it has been shown that estrogen receptors mediate the 
downregulation of AT1R but upregulation of AT2R in rodents (Armando et al., 2002; 
Baiardi et al., 2005; Rodriguez-Perez et al., 2012). Consistent with the present findings, 
sex differences in perinatal stress mediated epigenetic programming of gene expression 
patterns and subsequent disease development have been well reported previously with 
males often being prone to be at higher risk of disease development at an earlier age than 
females (Barker and Osmond, 1986; Bateson et al., 2004; Gluckman et al., 2008; 
McMillen and Robinson, 2005). 
The present investigation provides novel evidence that perinatal nicotine exposure 
increases brain susceptibility to HI injury through reprogramming of AT1R and AT2R 
expression patterns in rat pups. Although it may be difficult to translate the present 
findings directly into humans, the possibility that antenatal stresses may result in 
programming of specific gene expression patterns in the developing brain resulting in 
heightened vulnerability of newborn brains to HI injury provides a mechanistic 
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understanding worthy of investigation in humans. The clinical significance of the present 
study is warranted because maternal cigarette smoking and use of nicotine gum and patch 
during gestation present a major stress to the developing fetus and because HIE in 
newborns causes severe mortality and long-lasting morbidity yet the underlying 
mechanisms remain largely elusive. Further studies on the epigenetic regulation of AT1R 
and AT2R gene expression patterns in the developing brain should provide more insights 
into mechanisms at the molecular level and may suggest new insights of therapeutic 
strategies that may be beneficial for the treatment of HIE in newborns. 
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Abstract 
Perinatal nicotine exposure down-regulated angiotensin II type 2 receptor (AT2R) 
in the developing brain and increased brain vulnerability to hypoxic-ischemic injury in 
male neonatal rats. We tested the hypothesis that site-specific CpG methylation at AT2R 
gene promoter contributes to the increased vulnerability of brain injury in the neonate. 
Nicotine was administered to pregnant rats from day 4 of gestation to day 10 after birth. 
Brain hypoxic-ischemic injury was induced in day 10 male pups. CpG methylation at 
AT2R promoter was determined in the brain by quantitative methylation-specific PCR.  
Nicotine exposure significantly increased methylation of CpG-52 near the TATA-box at 
AT2R promoter. Electrophoretic mobility shift assay indicated that methylation of CpG-52 
significantly decreased the binding affinity of TATA-binding protein (TBP). Chromatin 
immunoprecipitation assay further demonstrated an increase in the binding of methyl-
binding protein (MeCP2) and a decrease in TBP binding to AT2R promoter in vivo in 
neonatal brains of nicotine-treated animals. This resulted in AT2R gene repression in the 
brain. Intracerebroventricular administration of 5-aza-2’-deoxycytidine abrogated the 
enhanced methylation of CpG-52, rescued the TBP binding, and restored AT2R 
expression. Of importance, 5-aza-2’-deoxycytidine reversed the nicotine-increased 
vulnerability of brain hypoxic-ischemic injury in the pups. The finding provides 
mechanistic evidence of increased promoter methylation in the developing brain linking 
perinatal stress and a pathophysiological consequence of heightened vulnerability of 
hypoxic-ischemic encephalopathy in neonatal brains.  
 
Introduction 
Hypoxic-ischemic encephalopathy (HIE) is the most common cause of newborn 
62 
brain damage due to systemic asphyxia, which may occur prior, during or after birth. HIE 
causes severe mortality and long-lasting morbidity including cerebral palsy, seizure, and 
cognitive retardation in infants and children (Ferrieo, 2004; Verklan, 2009). Emerging 
evidence suggests that aberrant brain development due to fetal stress may underpin the 
pathogenesis of HIE (Jensen, 2006). Maternal smoking is the single most widespread 
perinatal insult in the world and it has been associated with adverse pregnancy outcomes 
for mother, fetus and the newborn. Recent studies have provided evidence linking 
perinatal nicotine exposure and the increased incidence of neurodevelopmental disorders, 
neurobehavioral deficits, impaired cognitive performance, and increased risk of affective 
disorders later in life (Wickstrom, 2007; Pauly and Slotkin, 2008). Indeed, our recent 
study in a rat model has demonstrated that perinatal nicotine exposure suppresses  
angiotensin II type 2 receptor (AT2R) expression in the developing brain, resulting in an 
increase in the vulnerability of HIE brain injury in a sex-dependent manner in male 
neonates (Li et al., 2012).  
The mechanisms underlying perinatal nicotine-mediated AT2R gene repression in 
the developing brain remain elusive. Recent studies suggested that CpG methylation in 
non-CpG island, sequence-specific transcription factor binding sites played an important 
role in epigenetic modification of gene expression patterns in the developing fetus in 
response to perinatal stress (Lawrence et al., 2011; Meyer et al., 2009; Patterson et al., 
2010; Xiong et al., 2010). DNA methylation is a chief mechanism for epigenetic 
modification of gene expression patterns and occurs at cytosine in the CpG dinucleotide 
sequence (Jaenisch and Bird, 2003; Jones and Takai, 2001; Reik and Dean, 2001). 
Methylation in promoter regions is generally associated with the repression of 
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transcription, leading to a long-term shutdown of the associated genes. Methylation of 
CpG islands in gene promoter regions alters chromatin structure and transcription. 
Similarly, methylation of a single CpG dinucleotide at sequence-specific transcription 
factor binding sites may repress gene expression through changes in the binding affinity 
of transcription factors by altering the major groove structure of DNA to which the DNA 
binding proteins bind (Campanero et al., 2000; Fujimoto et al., 2005; Zhu et al., 2003), as 
well as by recruiting methyl-CpG binding proteins (MBPs) (Jones and Laird, 1999; 
Wade, 2001).   Rat AT2R gene promoter has a TATA element at -48 from the transcription 
start site, and a single CpG-52 locus 3 bases upstream of the TATA-box is identified at the 
AT2R promoter (Xue et al., 2011).  It has been suggested that increased methylation of a 
single CpG locus 3 bases upstream of TATA-box represses gene expression (Kitazawa 
and Kitazawa, 2007). Herein, we present evidence that perinatal nicotine exposure 
increases methylation of a single CpG-52 locus near the TATA element at AT2R gene 
promoter, resulting in a decrease in the binding of TATA-binding protein (TBP) to AT2R 
promoter and a repression of AT2R gene expression in the developing brain. Of 
importance, a demethylating agent 5-aza-2’-deoxycytidine abrogated nicotine-induced 
CpG-52 methylation, rescued the TBP binding, restored AT2R expression, and reversed 
the heightened vulnerability of HIE in neonatal brains. 
 
Materials and Methods 
Experimental Animals 
Pregnant Sprague-Dawley rats were purchased from Charles River Laboratories 
(Portage, MI) and were randomly divided into 2 groups: (1) saline control; and (2) 
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nicotine administration through osmotic minipumps (4ug/kg/min) implanted 
subcutaneously from Day 4 of gestation to Day 10 after birth. All rats were allowed to 
give birth and further studies were conducted in male 10-day-old neonatal (P10) pups. 
Female neonatal pups were euthanized on postnatal day 12. All procedures and protocols 
were approved by the Institutional Animal Care and Use Committee of Loma Linda 
University and followed the guidelines by the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. 
 
Brain Hypoxic-Ischemic (HI) Treatment and 
Intracerebroventricular Injection 
As previously reported (Li et al., 2012), a modified Rice-Vannucci model was 
conducted in male P10 pups (Vannucci et al., 1999). Pups were anesthetized with 2% 
isoflurane and the right common carotid artery was ligated. After recovery for 1 hour, 
pups were treated with 8% O2 for 1.5 hours. 5-Aza (1mg/kg; Sigma-Aldrich), a DNA 
methylase inhibitor, was administered intracerebroventricularly on postnatal day 7 (P7), 
one dosage 3 days before HIE treatment. Briefly, pups were anesthetized and fixed on a 
stereotaxic apparatus (Stoelting, Wood Dale, IL). An incision was made on the skull 
surface and bregma was exposed. 5-Aza was injected at a rate of 1μL/min with a 10μL 
syringe (Stoelting) on the right hemisphere following the coordinates relative to bregma: 
2 mm posterior, 1.5 mm lateral, and 3.0 mm below the skull surface (Han and Holtzman, 
2000). The injection lasted 2 minutes and the needle was kept for additional 5 minutes 
before its removal. The incision was sutured. The same procedures were treated in the 
vehicle group. 
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Measurement of Infarct Size  
As previously described (Li et al., 2012), pups were anesthetized and euthanized 
48 hours after the HI treatment. Coronal slices of the brain (2 mm thick) were cut and 
immersed in a 2% solution of 2,3,5-triphenyltetrazolium chloride monohydrate (Sigma-
Aldrich) for 5 minutes at 37°C and then fixed by 10% formaldehyde overnight. Each 
slice was weighed, photographed separately, and the percentage of infarction area for 
each slice was analyzed by Image J software (Version 1.40; National Institutes of Health, 
Bethesda, MD), corrected by slice weight, summed for each brain, and expressed as a 
percentage of whole brain weight. 
 
Western Immunoblotting 
Brains were homogenized in a lysis buffer containing 150 mmol/L NaCl, 50 
mmol/L Tris HCl, 10 mmol/L EDTA, 0.1% Tween-20, 1% Triton, 0.1% β-
mercaptoethanol, 0.1 mmol/L phenylmethylsulfonyl fluoride, 5 μg/mL leupeptin, and 5 
μg/mL aprotinin, pH 7.4. Homogenates were centrifuged at 4°C for 10 minutes at 10 000 
g, and supernatants collected. Protein concentrations were determined using a protein 
assay kit (Bio-Rad, Hercules, CA). Samples with equal amounts of protein were loaded 
onto 10% polyacrylamide gel with 0.1% sodium dodecyl sulfate and separated by 
electrophoresis at 100 V for 120 minutes. Proteins were then transferred onto 
nitrocellulose membranes and probed with primary antibodies against AT2R (1:1000; 
Santa Cruz Biotechnology; Santa Cruz, CA) as described previously (Xue et al., 2011). 
After washing, membranes were incubated with secondary horseradish 
peroxidaseconjugated antibodies. Proteins were visualized with enhanced 
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chemiluminescence reagents, and blots were exposed to Hyperfilm. The results were 
analyzed with Kodak ID image analysis software. Band intensities were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
 
Real-Time RT-PCR 
RNA was extracted from brains and abundance of AT2R mRNA was determined 
by real-time reverse transcription-polymerase chain reaction using an Icycler Thermal 
cycler (Bio-Rad, Hercules, CA), as described previously (Xue et al., 2011). The AT2R 
primers used were: 5ʼ-caatctggctgtggctgactt-3ʼ (forward) and 5’-tgcacatcacaggtccaaaga-
3’ (reverse). Real-time reverse transcription–polymerase chain reaction was performed in 
a final volume of 25 μL. Each polymerase chain reaction mixture consisted of 600 
nmol/L of primers, 33 U of M-MLV reverse transcriptase (Promega, Madison, WI), and 
iQ SYBR Green Supermix (Bio-Rad) containing 0.625 U Taq polymerase, 400 μmol/L 
each of dATP, dCTP, dGTP, and dTTP, 100 mmol/L KCl, 16.6 mmol/L ammonium 
sulfate, 40 mmol/L Tris-HCl, 6 mmol/L MgSO4, SYBR Green I, 20 nmol/L fluorescing, 
and stabilizers. The following reverse transcription–polymerase chain reaction protocol 
was used: 42°C for 30 minutes, 95°C for 10 minutes followed by 40 cycles of 95°C for 
20 seconds, 56°C for 1 minute, 72°C for 20 seconds. Glyceraldehyde-3-phosphate 
dehydrogenase was used as an internal reference and serial dilutions of the positive 
control was performed on each plate to create a standard curve. Polymerase chain 
reaction was performed in triplicate, and threshold cycle numbers were averaged. 
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Quantitative Methylation-Specific Polymerase Chain Reaction 
(MSP) 
CpG methylation at rat AT2R gene promoter was determined as previously 
described (Lawrence et al., 2011; Patterson et al., 2010). Briefly, genomic DNA was 
isolated from brains of P10 pups using a GenElute Mammalian Genomic DNA Mini-Prep 
kit (Sigma), denatured with 2 N NaOH at 42°C for 15 minutes, treated with sodium 
bisulfite at 55°C for 16 hours, and purified by a Wizard DNA clean up system (Promega) 
and resuspended in 40 μL H2O. Bisulfite-treated DNA was used as a template for real-
time fluorogenic methylation-specific polymerase chain reaction at CpG-52 locus (forward 
primer, 5ʼ-ttttttggaaagttggtaagtgttta-3ʼ; reverse primer for C, 5ʼ-ctctaatttccttcttatatattca-3ʼ; 
reverse primer for Cm, 5’-ctctaatttccttcttatatattcg-3’). Real-time methylation-specific 
polymerase chain reaction was performed using the iQ SYBR Green Supermix with 
iCycler real-time polymerase chain reaction system (Bio-Rad). Data are presented as the 
percent of methylation at the region of interest (methylated CpG/methylated CpG + 
unmethylated CpG × 100), as described previously (Lawrence et al., 2011; Patterson et 
al., 2010). 
 
Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts were collected from brains using NXTRACT CelLytic Nuclear 
Extraction Kit (Sigma). The oligonucleotide probes with CpG-52 and 
mCpG-52 of the TBP 
binding site at rat AT2R promoter region were labeled and subjected to gel shift assays 
using the Biotin 3’end labeling kit and Light-Shift Chemiluminescent EMSA Kit (Pierce 
Biotechnology, Rockford, IL), as previously described(Lawrence et al., 2011; Patterson 
et al., 2010). Briefly, single stranded oligos were incubated with Terminal 
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Deoxynucleotidyl Transferase (TdT) and Biotin- 11-dUTP in binding mixture for 30 min 
at 37ºC. The TdT adds a biotin labeled dUTP to the 3’-end of the oligonucleotides. The 
oligos were extracted using chloroform and isoamyl alcohol to remove the enzyme and 
unincorporated biotin-11-dUTP. Dot blots were performed to ensure the oligos were 
labeled equally. Combining sense and antisense oligos and exposing to 95ºC for 5 min 
was done to anneal complementary oligos. The labeled oligonucleotides were then 
incubated with or without nuclear extracts in the binding buffer (from Light-Shift kit). 
Binding reactions were performed in 20 μL containing 50 fmol oligonucleotide probes, 
1× binding buffer, 1 μg of poly (dI-dC), and 10 μg of nuclear extracts. For competitions 
studies, increasing concentrations of non-labeled oligonucleotides were added to binding 
reactions. For super-shift assay, 2 μL of affinity purified TBP antibody (Active Motif) 
was added to the binding reaction. The samples were then run on a native 5% 
polyacrylamide gel. The contents of the gel were then transferred to a nylon membrane 
(Pierce) and crosslinked to the membrane using a UV crosslinker (125 mJoules/cm2). 
Membranes were blocked and then visualized using the reagents provided in the 
LightShift kit. 
 
Chromatin Immunoprecipitation Assay (ChIP) 
Chromatin extracts were prepared from brains of male P10 rat pups. ChIP assays 
were performed using the ChIP-IT kit (Active Motif), as previously described (Patterson 
et al., 2010; Meyer et al., 2009). Briefly, brain tissues were incubated with 1% 
formaldehyde for 10 min to crosslink and maintain DNA/protein interactions. After the 
reactions were stopped with glycine, tissues were washed, and chromatin was isolated 
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and sheared into medium fragments (200 – 1000 base pairs) using a sonicator. ChIP 
reactions were performed using an antibody against TBP or MeCP2 to precipitate the 
transcription factor/DNA complex. Crosslinking was then reversed using a salt solution 
and the proteins were digested with proteinase K. Primer flanking the TBP binding site 
were used for quantitative RT-PCR: 5’-tctggaaagctggcaagtgt- 3’ (forward) and 5’-
tgggatgtaactgcaccaga- 3’ (reverse). PCR amplification products were visualized on 3% 
agarose gel stained with ethidium bromide. To quantify PCR amplification, 45 cycles of 
real-time PCR were carried out with 3 min initial denaturation followed by 95°C for 30 s, 
57°C for 30 s, and 72°C for 30 s, using the iQ SYBR Green Supermix with iCycler real-
time PCR system (Bio-Rad, Hercules, CA). All reactions were repeated in triplicate and 
the results were calculated as the ratio of immunoprecipitated DNA over input DNA. 
 
Statistical Analysis 
Data are expressed as mean ± SEM. Experimental number (n) represents neonates 
from different dams. Statistical significance (P<0.05) was determined by analysis of 
variance followed by Neuman-Keuls post hoc testing or Student t test, where appropriate. 
 
Results 
Methylation of CpG-52 Locus Inhibited TBP Binding Affinity 
Previously, we demonstrated that deletion of the TATA-box at rat AT2R promoter 
region resulted in a significant decrease in AT2R promoter activity (Xue et al., 2011). To 
demonstrate the binding of TATA-binding protein (TBP) to the TATA element at AT2R 
promoter, electrophoretic mobility shift assays were performed. Incubation of nuclear 
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extracts from pup brains with double-stranded oligonucleotide probes encompassing the 
TATA element resulted in the appearance of a major DNA-protein complex (Figure 12, 
lane 2), which was blocked by 200-fold excess of unlabeled oligonucleotide probes in 
cold competition (Figure 12, lane 4). Super-shift analysis showed that a TBP antibody 
caused super-shifting of the DNA-protein complex (Figure 12, lane 3).  A single CpG-52 
locus 3 bases upstream of the TATA-box was identified at rat AT2R promoter (Xue et al., 
2011). To determine whether methylation of CpG-52 locus inhibits TBP binding, the 
binding affinity of TBP to oligonucleotide probes with the TATA element containing 
either methylated or unmethylated CpG-52 locus was determined by competitive EMSA 
performed in pooled nuclear extracts from pup brains with the increasing ratio of 
unlabeled/labeled oligonucleotides encompassing the TATA element. As shown in Figure 
13, methylation of CpG-52 locus resulted in a significant decrease in the TBP binding 
affinity to the TATA element.   
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Figure 12. Binding of TBP to TATA element at AT2R promoter in rat pup brains. 
Nuclear extracts (NE) from pup brains were incubated with double-stranded 
oligonucleotide probes containing the TATA element at -48 in the absence or presence of 
a TBP antibody. Cold competition was performed with unlabeled competitor 
oligonucleotide at a 200-fold molar excess.  
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Figure 13. CpG-52 methylation inhibited TBP binding affinity at AT2R promoter. The 
binding affinity of TBP to the TATA element was determined in competition studies 
performed in pooled nuclear extracts from pup brains with the increasing ratio of 
unlabelled/labelled oligonucleotides encompassing the TATA element at -48 with 
unmethylated (UM) or methylated (M) CpG-52 locus.   
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5-Aza-2’-deoxycytidine Abrogated Nicotine-Induced Methylation 
of CpG-52 Locus and Restored AT2R Expression 
The previous study demonstrated that perinatal nicotine exposure resulted in a 
down-regulation of AT2R expression in the developing brain (Li et al., 2012). To 
determine the causal role of CpG-52 locus methylation in the nicotine-mediated down-
regulation of AT2R in pup brains, we measured methylation status of the CpG-52 locus at 
AT2R promoter in male pups in the control and nicotine-treated animals. As shown in 
Figure 14, the nicotine treatment significantly increased methylation of the CpG-52 locus. 
Of importance, the treatment of pups with a DNA demethylating agent 5-aza-2’-
deoxycytodine abrogated the nicotine-induced methylation (Figure 14). We further 
investigated the functional significance of the nicotine-mediated methylation in 
regulating TBP binding to AT2R promoter in vivo in the context of intact chromatin via a 
ChIP approach.  As shown in Figure 15, the increased methylation of CpG-52 locus by 
nicotine resulted in a significant increase in the binding of MeCP2 and a decrease in the 
binding of TBP to the TATA element at AT2R promoter in pup brains.  5-aza-2’-
deoxycytodine blocked these nicotine-induced effects (Figure 15). Consistently, 5-aza-2’-
deoxycytodine restored the nicotine-induced down-regulation of AT2R mRNA and 
protein expression in the brains (Figure 16).    
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Figure 14. 5-Aza-2’-deoxycytidine abrogated nicotine-induced methylation of CpG-52 
locus. Methylation of CpG-52 locus at AT2R promoter was determined in pup brains 
isolated from control and nicotine-treated animals in the absence or presence of 5-aza-2’-
deoxycytidine (AZA). Data are means ± SEM, n = 5. *P < 0.05 versus control group.     
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Figure 15. 5-Aza-2’-deoxycytidine reversed nicotine-induced changes in TBP and 
MeCP2 binding at AT2R promoter. TBP and MeCP2 binding to the TATA element at 
AT2R promoter in vivo in the context of intact chromatin was determined with ChIP 
assays in pup brains from control and nicotine-treated animals in the absence or presence 
of 5-aza-2’-deoxycytidine (AZA). Data are means ± SEM, n = 5. *P < 0.05 versus 
control group. 
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Figure 16. 5-Aza-2’-deoxycytidine restored nicotine-induced down-regulation of AT2R 
mRNA and protein expression. AT2R mRNA and protein abundance was determined in 
pup brains from control and nicotine-treated animals in the absence or presence of 5-aza-
2’-deoxycytidine (AZA). Data are means ± SEM, n = 5. *P < 0.05 versus control group. 
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5-Aza-2’-deoxycytidine Rescued Nicotine-Induced Vulnerability 
of HI Injury in Pup Brains 
AT2R played a critical role in protecting neonatal brains from HI injury (Li et al., 
2012). We thus investigated the causal role of nicotine-induced epigenetic down-
regulation of AT2R in the heightened vulnerability of pup brains to HI injury by 
determining whether 5-aza-2’-deoxycytodine-mediated restoration of AT2R expression in 
the developing brain reversed nicotine-induced vulnerability of HI injury in pup brains.  
As shown in Figure 17, in the absence of 5-aza-2’-deoxycytodine, the nicotine treatment 
resulted in a significant increase in HI injury in pup brains, which was abolished by 5-
aza-2’-deoxycytodine. Whereas the nicotine treatment decreased the body weight (15.9 ± 
1.4 g vs. 18.4 ± 0.4 g, P < 0.05) but increased the brain to body weight ratio (0.06 ± 0.00 
vs. 0.05 ± 0.00, P < 0.05) in the pups, the treatment of 5-aza-2’-deoxycytodine had no 
significant effect on the gross development of neonates in either control or nicotine-
treated groups.  Thus, the body weight in the absence or presence of 5-aza-2’-
deoxycytodine were 18.4 ± 0.4 g vs. 17.8 ± 0.4 (P > 0.05) in control pups, and 15.9 ± 1.4 
g vs. 15.7 ± 1.0 g (P > 0.05) in nicotine-treated animals. The brain to body weight ratio in 
the absence or presence of 5-aza-2’-deoxycytodine were 0.05 ± 0.00 vs. 0.05 ± 0.00 (P > 
0.05) in control pups, and 0.06 ± 0.00 vs. 0.06 ± 0.00 (P > 0.05) in nicotine-treated 
animals.  
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Figure 17. 5-Aza-2’-deoxycytidine rescued nicotine-induced increase in neonatal brain 
HI injury.  Hypoxic-ischemic injury was determined in pup brains from control and 
nicotine-treated animals in the absence or presence of 5-aza-2’-deoxycytidine (AZA). 
Data are means ± SEM, n = 4 to 7. *P < 0.05 versus control group.    
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Discussion 
The present study reveals evidence that heightened methylation of a single CpG-52 
locus adjacent to the TATA element at AT2R promoter significantly inhibits the binding 
activity of TBP and suppresses AT2R mRNA and protein expression in the developing 
brain in response to perinatal nicotine exposure. Of importance, the findings that DNA 
demethylating agent 5-aza-2’-deoxycytodine blocked nicotine-induced methylation, 
restored AT2R expression, and rescued the heightened brain susceptibility to HI injury in 
pups, provide novel evidence of a causal role of gene-specific promoter methylation in 
perinatal stress-mediated HIE vulnerability in the neonate. 
In the previous study, we have reported in a rat model that maternal nicotine 
administration increases HIE-induced brain injury in male but not female rat pups via 
reprogramming the expression patterns of AT2R in a sex-specific manner in the 
developing brain (Li et al., 2012). Both AT1R and AT2R have been implicated in the 
pathogenesis of neonatal HIE and confer neuroprotective traits. Nicotine treatment 
significantly repressed expression levels of AT2R mRNA and protein in the brain of male 
pups but up-regulated its expression in female pups, demonstrating a sex-specific effect. 
The finding that AT2R agonist CGP42112 reversed the nicotine-induced increase in brain 
HI injury demonstrated an important role of brain AT2R repression  in programming of 
enhanced vulnerability of neonatal HIE. However, the underlying molecular mechanisms 
of perinatal nicotine exposure in repressing AT2R gene transcription in neonatal brains 
remained elusive. 
Rat AT2R gene promoter has a TATA element at -48 from the transcription start 
site (Xue et al., 2011). In the present study, we demonstrated that an antiserum to TATA-
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box binding protein caused super-shifting of the DNA-protein complex resulting from the 
binding of nuclear extracts from pup brains with the double-stranded oligonucleotide 
probes containing the TATA element, indicating a consensus TATA binding site at AT2R 
promoter in rat brains. The functional significance of the TATA element in the regulation 
of rat AT2R gene activity was demonstrated by the finding that deletion of TATA 
significantly decreased the AT2R promoter activity (Xue et al., 2011). The present 
finding that methylation of a single CpG-52 locus 3 bases upstream of the TATA-box 
significantly decreased the binding affinity of TATA-box binding protein to the TATA 
element is intriguing and indicates an important epigenetic mechanism of CpG 
methylation at a sequence-specific binding site in inhibiting transcription factor binding 
and a gene repression in the developing brain. Although the transcriptional regulation by 
DNA methylation is often observed in CpG islands located around the promoter region 
via the sequence-nonspecific and methylation-specific binding of inhibiting methylated 
CpG-binding proteins (Jones and Laird, 1999; Wade, 2001), DNA methylation of 
sequence-specific transcription factor binding sites can alter gene expression through 
changes in the binding affinity of transcription factors by altering the major groove 
structure of DNA to which the DNA-binding proteins bind (Campanero et al., 2000; 
Fujimoto et al., 2005; Zhu et al., 2003). In agreement with the present finding, previous 
studies demonstrated that fetal stress resulted in an increase in sequence-specific CpG 
methylation at Sp1 and Egr1 binding sites at protein kinase C ε gene (PKCε) promoter 
and PKCε gene repression in the developing heart (Lawrence et al., 2011; Meyer et al., 
2009; Patterson et al., 2010). In addition, it has been demonstrated that increased 
methylation at a CpG locus 3 bases upstream of TATA-box inhibits the binding of the 
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TATA-box binding protein and decreases receptor activator of nuclear factor-κB ligand 
gene promoter activity (Kitazawa and Kitazawa, 2007). 
The finding that nicotine treatment significantly increased methylation of CpG-52 
locus 3 bases upstream of TATA-box at the AT2R promoter in pup brains reveals an 
important mechanism of site-specific CpG methylation in epigenetic repression of AT2R 
gene in the developing brain. This notion is further supported by the results of chromatin 
immunoprecipitation assays in the present study, demonstrating that the nicotine-induced 
increase in methylation of the CpG-52 locus inhibited the binding of TATA-box binding 
protein to the TATA element at the AT2R promoter in vivo in pup brains in the context of 
intact chromatin. A mechanism of CpG methylation-mediated inhibition of transcription 
factor binding is via the binding of methyl-CpG binding proteins (MBPs) (Jones and 
Laird, 1999; Wade, 2001).  MBPs that bind to single or multiple CpGs interact with a co-
repressor complex containing histone deacetylases and other chromatin remodeling 
factors, which make local chromatin structure more condensed and less accessible to 
transcription factor binding (Jaenisch and Bird, 2003; Jones at al., 1998; Nan et al., 
1998). The mammalian MBP family consists of MeCP2, MBD1, MBD2, MBD3, and 
MBD4. Differences in affinities of MBPs for different CpG-methylated DNA sequences 
may play a role in selective recruitment of MBPs to gene promoters (Fraga et al., 2003). 
For example, a complex of MBD2 and several NuRD chromatin remodeling proteins, 
initially called MeCP1, binds to DNA containing at least 12 symmetrically methylated 
CpGs (Meehan et al., 1989), whereas MeCP2 binds to a single methylated CpG (Ballestar 
and Wolffe, 2001). In the present study, we demonstrated that the nicotine treatment 
significantly increased the binding of MeCP2 to the CpG-52 locus at AT2R promoter in 
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pup brains in vivo in the context of intact chromatin, suggesting a novel mechanism in 
sequence-nonspecific CpG methylation and gene repression in the developing brain 
resulting from perinatal stress. Consistently, it has been demonstrated that the binding of 
MeCP2 at the TATA-box region may directly repel the binding of TATA-box binding 
protein to the TATA element (Kitazawa and Kitazawa, 2007). 
Of importance, the present study provides the cause-and-effect evidence in the 
perinatal stress-induced increase in CpG methylation and AT2R gene repression in the 
developing brain and its pathophysiological consequence of heightened HIE vulnerability 
in the neonate. Epigenetic states of DNA methylation are reversible. The causal effect of 
increased CpG-52 methylation in the nicotine-induced AT2R gene repression in the brain 
was demonstrated with a DNA methylation inhibitor 5-aza-2’-deoxycytidine in the 
present study.  5-Aza-2’-deoxycytidine, via inhibition of DNA methyltransferase 1, has 
been demonstrated to cause demethylation of genes and rescue gene expressions both in 
vivo and in vitro, and has been widely used to inhibit DNA methylation (Alikhani-
Koopaei et al., 2004; Altundag et al., 2004; Creusot et al., 1982; Jaenisch and Bird, 2003; 
Lin et al., 2001; Michalowsky and Jones, 1987; Pinzone et al., 2004;  Richardson, 2002; 
Scheinbart et al., 1991; Segura-Pacheco et al., 2003; Villar-Garea et al., 2003). In the 
present study, we demonstrated that ICV administration of 5-aza-2’-deoxycytidine 
reversed the nicotine-induced CpG-52 methylation, rescued TBP binding and restored 
AT2R mRNA and protein expression in the developing brain. In agreement to the present 
finding, a previous study in rats demonstrated that intraperitoneal injection of 5-aza-2’-
deoxycytidine caused demethylation of 11-hydroxysteroid dehydrogenase type 2 (11-
HSD2) gene promoter in the kidney, lung, and liver (Alikhani-Koopaei et al., 2004).  
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These in vivo changes induced by 5-aza-2’-deoxycytidine were compatible with a decline 
in 11-HSD2 promoter DNA methylation in cell lines, and the decreased level of 
promoter methylation resulted in a higher expression of the 11-HSD2 gene both in vivo 
and in vitro (Alikhani-Koopaei et al., 2004).  The ability of 5-aza-2’-deoxycytidine to 
rescue a gene expression in the presence of fetal stress has also been demonstrated in the 
developing heart showing that 5-aza-2’-deoxycytidine restores fetal stress-induced down-
regulation of PKCε mRNA and protein expression in fetal rat hearts (Lawrence et al., 
2011; Meyer et al., 2009; Patterson et al., 2010; Xiong et al., 2010).  The finding that 5-
aza-2’-deoxycytidine abrogated the nicotine-induced increase in the vulnerability of HI 
injury in the pup brains provides novel and causative evidence of increased promoter 
methylation linking perinatal stress and pathophysiological consequence of heightened 
HIE vulnerability in the neonate. 
The present investigation provides evidence of a novel mechanism of increased 
methylation of a single CpG-52 near the TATA element in epigenetic repression of gene 
expression patterns in the developing brain and the resultant increase in HIE vulnerability 
in neonatal brains caused by fetal and neonatal stress. Although it may be difficult to 
translate the present findings directly into the humans, the possibility that perinatal 
nicotine exposure may result in programming of a specific gene expression in the brain 
with a consequence of increased brain HI injury in the neonate, provides a mechanism 
worthy of investigation in humans. This is because maternal cigarette smoking and use of 
nicotine gum and patch are a major stress to the developing fetus and newborn. Of 
importance, the present finding that inhibition of DNA methylation rescued perinatal 
stress-induced programming of ischemic-sensitive phenotype in the developing brain 
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provides a mechanistic understanding of pathophysiology of HIE and may suggest new 
insights in the development of therapeutic strategies in the treatment of HIE in the 
neonate.  
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CHAPTOR FOUR 
GENERAL DISCUSSION 
 
Perinatal Nicotine Exposure, Oxidative Stress and Aberrant 
Promoter Methylation 
Our present study already demonstrated a close linkage of nicotine induced 
heightened CpG methylation status at AT2R promoter, repression of AT2R gene 
expression and enhanced vulnerability to neonatal HIE. However, the pathogenic 
mechanisms underpinning nicotine exposure and hypermethylation status at AT2R 
promoter remains poorly understood. Recently, more and more evidence most 
specifically derived from various carcinogenesis researches revealed the potential 
association between prolonged oxidative stress exposure and aberrant promoter DNA 
methylation patterns, which may also shed light on our present study. 
In general, oxidative stress indicates a cellular state of which the ROS production 
outweighs the cell’s ability to metabolize or decompose them leading to excessive 
accumulation of ROS that overwhelms cellular defenses (Ziech et al., 2011). The 
carcinogenicity of oxidative stress is primarily attributed to the genotoxicity of ROS in 
diverse cellular processes, such as modification of DNA bases, strand breaks, DNA-
protein cross linkages, etc. (Lee and Lee, 2006). Except for causing genetic changes, 
ROS may also lead to epigenetic alterations which may influence the genome and play a 
key role in the development of human carcinogenesis (Campos et al, 2007). More 
specifically, ROS production is correlated to alterations in DNA methylation patterns 
(Donkena et al., 2010; Ziech et al., 2010). Intriguingly, ROS-induced aberrant DNA 
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methylation demonstrates bidirectional effects, hypo- or hyper- methylation. Particularly, 
ROS production induced DNA lesions (such as 8-hydroxyl-2-deoxyguanosine; 8-
hydroxyguanine; 8- OHdG [Weitzman et al., 1994; Turk et al., 1995a, 1995b; Kuchino et 
al., 1987], O6-methylguanine [Hepburn et al., 1991; Tan and Li,1990] and single stranded 
DNA [Christman et al., 1995]) have been demonstrated to contribute to decreased DNA 
methylation by means of interfering with the ability of DNA to function as a substrate for 
the DNA methyltransferases (DNMTs) and thus resulting in global hypomethylation 
(Franco et al., 2006), which may induce both genomic instability and activation of 
protooncogenes, resulting in human carcinogenesis. Alternatively, ROS-induced 
oxidative stress can also suppress gene expression by mechanisms that involve aberrant 
hypermethylation of tumor suppressor gene at promoter regions and thus lead to 
programming of the malignant phenotypes, which is also similar to the observations in 
our recent studies. For example, one study demonstrated that exposure of hepatocellular 
carcinoma cells to hydrogen peroxide (H2O2) induced hypermethylation of the E-cadherin 
gene promoter (a tumor suppressor gene) via increasing the expression of Snail (a 
transcription factor that down-regulates the expression of E-cadherin) which then induced 
methylation at the promoter of E-cadherin gene by recruiting histone deacetylase 1 and 
DNA methyltransferase 1 (Lim et al., 2008). In fact, many tumor suppressor genes are 
repressed via ROS-mediated aberrant methylation of CpG island-rich promoter regions 
(Ushijima and Takada, 2005). Recent genome-wide screening of tumor DNA has also led 
to the identification of several tumor-suppressor genes displaying oxidative stress-
induced alterations in methylation patterns (Ziech et al., 2011), suggesting the critical 
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roles of oxidative stress exposure induced aberrant promoter methylation patterns of 
selective genes in human carcinogenesis.  
Both human and animal studies have already verified that maternal smoking can 
induce oxidative damage in both the mother and the fetus (Strakovsky and Pan, 2012). A 
recent transcriptome analysis of pregnant smokers and non-smokers demonstrated that 
smoking was associated with altered expression patterns of numerous oxidative stress 
related genes in peripheral blood, placenta, and cord blood, suggesting that smoking can 
significantly influence oxidative balance in both maternal and fetal tissues (Votavova et 
al., 2011). In addition, treatment of fetal explants cultures with cigarette smoke extract 
resulted in an increase of the markers of oxidative stress and a decrease in antiapoptotic 
markers (Menon et al., 2011). In rats, maternal nicotine administration enhanced arterial 
contractions and contributed to hypertension in the offspring, and this was associated 
with decreased SOD activity, and increased superoxide, MDA, and nitrotyrosine protein 
levels in the vascular walls of adult offspring (Xiao et al., 2011). Additionally, offspring 
of rats with prenatal nicotine exposure presented severe pancreatic islet oxidative stress, 
mitochondrial abnormalities, glucose intolerance, and reduced glucose-stimulated insulin 
secretion, indicating that prenatal nicotine exposure induced a diabetic phenotype in 
offspring (Bruin et al., 2008). All of evidence clearly indicates that nicotine exposure 
may induce extensive oxidative stress in various organs or tissues of both the mother and 
the fetus.    
Thus, it is presumable that, directly or indirectly, perinatal nicotine exposure may 
also induce sustained oxidative damage in mother and fetus, allowing the fetal brain 
exposure to prolonged   high levels of oxidative stress and contribute to aberrant 
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promoter DNA methylation patterns of selective genes as observed in carcinogenesis. 
Study has shown that maternal nicotine exposure treatment can increase norepinephrine 
levels in fetal rat brains (Onal et al., 2004), which may act as a vital mediator to induce 
heightened oxidative stress and contribute to hypermethylation status of protective genes 
at promoter region. In fact, our recent researches have demonstrated maternal nicotine 
administration induced heightened CpG methylation at Egr-1 and Sp-1 binding sites in 
PKCƐ promoter, repressed PKCƐ gene expression and caused enhanced cardiac 
vulnerability to ischemia and reperfusion injury in adult rat offspring (Lawrence et al., 
2011). Of interest, our subsequent study revealed it is not nicotine itself but increased 
levels of norepinephrine triggered by nicotine exposure causes CpG methylation of 
transcription factor binding sites at PKCƐ promoter in rodent hearts via activating Nox1-
dependent reactive oxygen species production (Lawrence et al., 2011; Xiong et al., 2012), 
suggesting a critical role of prolonged oxidative stress in heightened promoter 
methylation patterns. Likewise, another research indicates that maternal hypoxia 
exposure-induced oxidative stress increases CpG methylation of the SP-1 binding sites at 
PKCƐ promoter in fetal hearts and H9c2 cells which can be blocked by ROS scavengers 
(Patterson et al., 2012). Taken together, it is possible that prolonged oxidative stress 
exposure may be one of the most common pathways to induce aberrant promoter 
methylation patterns in response to various exogenous and endogenous stressful stimuli 
including perinatal nicotine exposure and reprogramming of gene expression and 
vulnerability to postnatal life challenges, which deserves further extensive investigations.   
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Fetal Stress Reprograms Ischemic-Sensitive Phenotype in the 
Developing Brain: Other Potential Candidates  
In chapter two and three, we have demonstrated that perinatal nicotine exposure 
epigenetically reprograms expression patterns of AT1R/AT2R in the developing brain and 
causes heightened susceptibility to neonatal hypoxic-ischemic encephalopathy in a sex-
specific manner. Given that the potential diverse stressful insults might be experienced by 
mother and its profound reprogramming effects on the fetal brain structure and function, 
it is plausible that there are other vital candidates implicated in the complex 
pathophysiology of ischemic brain injury and contribute to determination of the 
susceptibility to neonatal HIE in postnatal life, not only limited to AT1R/AT2R. Indeed, 
there is a multitude of promising players may be involved in such pathological processes. 
The first promising candidate mediator with potential role in heightened 
vulnerability of neonatal HIE is glucocorticoid, either cortisol or corticosterone. As 
described in introduction part, glucocorticoid exerts profound effects on the programming 
of fetal stress and brain development, particularly their programming effects on the HPA 
axis activity as well as other important organs and tissues. Sustained overexposure to 
glucocorticoid down-regulates GR levels in hippocampus, attenuates negative feedback 
of the HPA axis, permanently resets the activity of HPA axis and enhances basal and 
stressful glucocorticoid responses in the postnatal life. These will cause the brain to be 
exposed to chronically high level of glucocorticoid, resulting in aberrant gene regulation 
and cell behavior and programming of vulnerability of HIE injury. Paradoxically, 
glucocorticoid shows bidirectional effects on the brain, which may be implicated in both 
neurodegenerative and neuroprotective processes (Abraham et al., 2001). On the one 
hand, glucocorticoid may inhibit key nutrients such as glucose uptake, modulate both 
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excitatory and inhibitory neurotransmission, increase intracellular calcium 
concentrations, enhance excitotoxicity and induce perturbation of 11β-HSD, which may 
retard fetal brain growth, delay myelination, promote synapse degeneration and enhance 
neuronal vulnerability to hypoxic/ischemic insults (Abraham et al., 1996; Doyle et al., 
1993; Joels and de Kloet, 1994; Moghaddam et al., 1994; Seckl and Walker, 2001). On 
the other hand, some studies indicate via modulating calcium currents, increasing 
synthesis of neurotrophic factors, such as lipocortin-1, basic fibroblast growth factor 
(bFGF), nerve growth factor (NGF), and decreasing lipid peroxidation, glucocorticoid 
may be neuroprotective (Flower and Rothwell, 1994; Joels and de Kloet, 1994; Mocchetti 
et al., 1996; Young and Flamm, 1982). There are experimental findings suggesting that 
glucocorticoid affects the vulnerability of fetal and neonatal brain to hypoxia-ischemia 
challenge. However, the results were inconsistent, contradictory, and dependent on 
experimental protocol, dosage, time, animal age, strains and species (Flavin, 1996; 
Kauffman et al., 1994; Tombaughet al., 1992; Tuor, 1995, 1997; Whitelaw and Thoresen, 
2000). It appears that the concentration and duration of glucocorticoid treatment are the 
two key factors determining the detrimental or beneficial effects of glucocorticoid in the 
brain. Exposure to long term and high levels of glucocorticoid enhances neurotoxic 
effects in brain injury, such as in HIE, whereas physiological or slightly higher (slightly 
supraphysiological elevated levels in a narrow concentration window) levels of 
glucocorticoid may confer on the brain protective potential to challenges (Abraham et al., 
2001). Although there are some controversial reports in the literature, the notion has been 
widely accepted that overexposure to glucocorticoid enhances neuronal degeneration 
(Abraham et al., 2001). Given that most prenatal stress increases both basal and stressful 
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glucocorticoid levels in offspring mainly via reprogramming of the HPA axis, which may 
contribute to enhanced vulnerability of neonatal HIE and other challenges, it is plausible 
that glucocorticoid itself may be a pivotal mediator in such pathophysiological processes. 
However, such effects may be variable depending on the duration, timing, severity and 
types of prenatal stresses. 
Fetal stress may also reprogram expression patterns of matrix metalloproteinases 
(MMPs) in the neonatal brain, which contribute to the enhanced vulnerability of HIE. 
MMPs belong to a family of zinc-dependent proteases that exert pronounced effects in 
the ECM turnover. These enzymes remodel almost all components of the matrix and play 
an essential role in cell signaling regulation, cell survival and cell death. MMPs, 
especially MMP-2, MMP-3 and MMP-9, may target the extracellular matrix of blood 
vessels, basal lamina, and tight junctions in endothelial cells, increase the permeability of 
the blood-brain barrier in neuroinflammation due to hypoxia-ischemia, multiple sclerosis 
and CNS infection, which can result in cytotoxic and vasogenic edema, promote 
hemorrhagic transformation, induce apoptosis of neurons and oligodendrocytes 
(Cunningham et al., 2005; Rosenberg, 2009). However, in later stage of such pathology, 
MMPs play critical roles in tissue repair and remodeling process via inducing 
angiogenesis and neurogenesis. Growing evidence suggests that overly upregulated 
activity/expression of MMPs, particularly MMP-2 and MMP-9, are deleterious in the 
acute phase of stroke. Inhibition of MMPs in the acute phase may reduce the damage to 
BBB (Gasche et al., 2001). There is a report indicating decreased damage to BBB and 
reduced infarct size in a focal ischemic MMP-9 knockout model (Asahi et al., 2001). 
More importantly, a recent study in a neonatal rat HIE model revealed that early 
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inhibition of MMPs conferred acute and long-term beneficial effects via reducing tight 
junction proteins degradation, attenuating the permeability of BBB, improving brain 
edema, and preventing brain atrophy (Chen et al., 2009a). Fetal hypoxia reprograms 
expression patterns of MMPs in the heart and brain and increases activities/expressions of 
both MMP-2 and MMP-9 in the neonatal brain (Tong et al., 2010, 2011; Tong and 
Zhang, 2011). Considering the evident detrimental effects of MMPs in the acute stroke 
models and other neurological pathophysiologies, it is plausible that altered expression 
patterns of MMPs by prenatal stress is another important mediator in programming of 
ischemic-sensitive phenotype and increased susceptibility of HIE in the neonatal brain. 
 Hypoxia inducible factor-1 (HIF-1), a key regulator in response to cellular 
hypoxia and oxygen homeostasis (Wang et al., 1995), may be profoundly involved in the 
programming effects of prenatal stress on the vulnerability to neonatal HIE. Being a 
heterodimeric transcription factor, HIF-1 consists of an oxygen-sensitive HIF-1α and a 
constitutively expressed HIF-1β. The normal oxygen level results in a rapid degradation 
of HIF-1α, but hypoxia can enhance the stability of HIF-1α and promote the 
transactivation of its target genes. More than 100 HIF-1α targeted genes have been 
identified up to now, including erythropoiesis, angiogenesis, cell proliferation (IGF-2), 
glucose metabolism (Glut-1,3), inflammation (COX-2), cell apoptosis (BNIP3, P53), 
vascular tone and matrix metabolism, etc. (Ke and Costa, 2006). Based on its regulation 
of a wide spectrum of genes in diverse contexts, the effects of HIF-1α activation may be 
very complex and variable, to some extent similar to those of glucocorticoids. During 
brain challenges, such as in hypoxia-ischemia, HIF-1α may be both anti-apoptotic via 
enhancing the transcription of EPO, VEGF, IGF-2 and GLUT-1, etc., but it also can be 
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pro-apoptotic by upregulation of factors such as COX-2, BNIP3 and P53 that contribute 
to cell death (Chen et al., 2009b; Fan et al., 2009). Notably, VEGF promotes the 
permeability of BBB and enhances brain edema in the acute phase of HI, which is 
different from its later beneficial effects such as neovascularization (Chen et al., 2009b). 
The bidirectional effects of HIF-1α in hypoxia may be affected by some factors, such as 
the duration and severity of hypoxia, and the type of pathological stimuli. Mild hypoxia 
may predominantly induce anti-apoptotic gene expression, but more sustained and severe 
hypoxia promotes pro-apoptotic gene expression (Chen et al., 2009b; Fan et al., 2009). In 
addition, effects of HIF-1α in HI may be cell type specific. In vitro studies suggest that 
functional loss of HIF-1α may be neuroprotective for astrocyte but enhances neuronal 
vulnerability to HI injury (Vangeison et al., 2008). Under normal conditions, HIF-1α is 
essential for normal fetal brain development via the activation of genes such as VEGF 
because of the relatively lower physiological oxygen level in uterus (Fan et al., 2009; Lee 
et al., 2001; Trollmann and Gassmann, 2009). In addition to maternal hypoxia, some 
other prenatal stresses, such as nicotine, cocaine, and ethanol exposure, may also trigger 
the release of catecholamine, resulting in various degrees of ischemia/hypoxia insult to 
the fetus and leading to a sustained or episodic upregulation of HIF-1α. Long-term and 
supraphysiological high levels of HIF-1α in the fetus, combined with its adverse impacts 
on the developing brain, may persist into the postnatal developmental stage and enhance 
the vulnerability of neonatal HIE injury. 
 There are some studies indicating that aberrant development of the 
monoaminergic system in specific brain regions and/or peripheral organs such as the 
heart and adrenals also weakens the tolerance to hypoxia/ischemia insults in neonates. It 
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is well recognized that prenatal nicotine exposure is a major risk factor for SIDS in which 
defective arousal and cardiorespiratory response adjustment are considered to be the 
potential mechanisms (Milerad and Sundell, 1993; Slotkin, 1998; Wickstrom, 2007). 
Prenatal nicotine exposure exerts negative effects on the development of central and 
peripheral catecholaminergic system by decreasing synthesizing enzymes and reducing 
synthesis and release of catecholamine in brainstem nucleus, adrenals and heart, which 
may particularly impact the crucial defensive response to acute stress including 
hypoxia/ischemia and enhance the vulnerability of neonatal HIE (Slotkin et al., 1987; 
Wickstrom et al., 2002). These detrimental effects in defensive responses appear to 
correlate with functional loss of some subtypes of nAChRs via activity-dependent 
desensitization (Cohen et al., 2002). A recent study in rhesus monkey also reported that 
prenatal nicotine exposure compromises the brainstem serotonergic pathways, another 
important neural structure implicated in autonomic function, arousal and 
cardiorespiratory responses to acute hypoxic/ischemic challenge (Slotkin et al., 2011).  
Evidently, the impacts of prenatal stress on fetal and neonatal brain development 
are very complicated, dynamic, variable and multifaceted, which may also be subtle or 
drastic, and are profoundly affected by exposure age, duration, protocol, severity and 
nature of stress stimuli, and genetic traits. The underlying mechanisms of neonatal HIE 
remain to be further elucidated. In addition to the common potential mediators mentioned 
above, there are other possible factors that may be involved in programming of the 
vulnerability of neonatal HIE under different types of prenatal stressor. For example, the 
decreased expression of some neurotrophic factors, such as BDNF; perturbation of 
neurotransmitters and their receptors, such as glutamate, GABA and NMDA; enhanced 
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oxidative stress; dysfunction of mitochondria; and inflammatory factors, may all act as 
potential mediators to alter the vulnerability of HIE in the neonatal brain (Archer, 2011; 
Levitt, 1998; Warner and Ozanne, 2010). 
 
Potential Interventional Targets of Neonatal HIE 
In our present study, we have demonstrated that both AT1R and AT2R are 
implicated in the pathogenesis of neonatal HIE and confer neuroprotective properties. 
Besides, administration of 5-Aza, a DNA methylase inhibitor, reverses nicotine exposure 
induced pathological changes at molecular, cellular and functional levels, suggesting that 
relatively stable epigenetic modification is still a reversible process and pharmacological 
epigenetic manipulation may be a feasible approach to treat HIE. However, just as 
discussed above, diverse potential mediators might be implicated in this complex brain 
injury process, indicating it is necessary to develop multifaceted, comprehensive and 
interdisciplinary strategy to overcome this catastrophic brain injury.       
Trying to avoid potential stress stimuli during pregnancy is essential for 
effectively preventing or ameliorating the adverse programming effects on fetal 
development. Quitting use of ethanol, cocaine and nicotine should be encouraged, which 
can be further supported by behavioral modifications and counseling strategies. Owing to 
the lack of solid evidence of its efficacy and safety, NRT should not be readily 
recommended to pregnant women until carefully weighing its potentially adverse effects 
on the fetus (Pauly and Slotkin, 2008; Slotkin, 1998). For pregnant women who are 
strongly indicated for glucocorticoid therapy, the selection of glucocorticoid and 
administration protocol are vital. Normally, 11β-HSD2 sensitive glucocorticoid should be 
favored and betamethasone may be preferred to dexamethasone, and low dosage 
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administration and fewer times of injection may be more beneficial to the fetus based on 
available clinical studies (Gulino et al., 2009; Heine and Rowitch, 2009; Whitelaw and 
Thoresen, 2000). It is also important to treat underlying systemic diseases to prevent or 
attenuate possible placental insufficiency and fetal ischemia/hypoxia and to improve 
maternal nutrition status with an optimal balanced diet supplying nutrients including 
various macro and/or micro nutrients when necessary. 
A wide variety of emerging evidence has suggested that epigenetic modifications 
of gene expression patterns exhibit a central role in fetal stress-mediated programming of 
neurological and cardiometabolic disorders in later life. Predictably, pharmacological 
manipulations of epigenetic mechanisms present a promising interventional strategy. 
Indeed, several experimental studies offered exciting results. As mentioned above, 
programming of the HPA axis provides an important common pathway for the alteration 
of vulnerability to various pathophysiologies in later life in which epigenetic 
modification of GR gene expression patterns in hippocampus plays a critical role. Animal 
studies conducted in high or low maternal LG offspring have revealed that central 
infusion of a HDAC inhibitor, trichostatin A (TSA) or methyl donor S-adenosyl-
methionine (SAM), can reverse the epigenetic modification status in GR promoter region, 
rescue the binding capacity of NGFI-A to exon 17 region, recover GR expression in 
hippocampus, restore the HPA axis activity, and reverse the increased vulnerability of 
neurological dysfunction in later life (Weaver et al., 2004, 2005). More importantly, these 
studies imply that it is still reversible for some gene expression controlled by lasting 
epigenetic modifications, and enriching postnatal environment, or providing 
pharmacological interventions may restore long-term aberrant programming effects. In 
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addition to HDAC inhibitors and DNA methylation inhibitors, other agents, such as 
plant-derived isoflavone genistein, leptin, folate, fish oil, omega-3 and vitamin D, can 
alter the corresponding abnormal epigenetic modification status and improve the adverse 
programming effects caused by prenatal stress (Gregorio et al., 2008; Hypponen et al., 
2007; Torrens et al., 2006; Vickers et al., 2008; Wyrwoll et al., 2007). However, up to 
now, most of epigenetic therapy compounds exert nonspecific modifications on genes 
and transposable elements, and thus their adverse effects should not be neglected, 
including inducing or inhibiting other non-responsible genes expression, the potential 
tumorigenesis and mutagenesis properties, as well as promoting cell-cycle arrest and 
apoptosis (Karpf et al., 2001; Laird et al., 1995). In general, current epigenetic therapy is 
still in its infancy. 
For the neonates at risk of HIE or already harmed by HIE, prevention and therapy 
are complex and somewhat frustrating. Timely diagnosis and therapy are crucial but are 
also very challenging, which greatly affects the final outcomes. If possible, various 
available clinical techniques, such as advanced neuroimaging, EEG, some reliable 
biomarkers of brain damage (e.g., S-100, NSE), should be employed to identify and 
monitor HIE injury in a timely manner (Perlman, 2006; Rees et al., 2011). Despite 
apparent limitations, moderate hypothermia is the only currently established available 
therapy for full-term newborns with mild to moderate HIE. A wealth of animal studies 
have conferred some promising interventional strategies, such as NMDA receptor 
blockade, NOS inhibition, prevention of apoptosis and free radical formation, 
administration of neurotrophic factors and growth factors, AT2 receptor stimulation, as 
well as early inhibition of MMPs and HIF-1α, all of which should enrich our 
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understanding of HIE pathophysiology and provide us with more potentially promising 
therapeutic options (Chen et al., 2009a,b; Perlman, 2006; Rees et al., 2011). 
 
Conclusions 
Neonatal HIE is one of the most common causes of brain injury which impacts 
greatly on human well being but lacks of sufficient effective interventions nowadays; 
maternal smoking represents the single most widespread perinatal insult in the world 
associated with adverse pregnancy outcomes for mother, fetus and the newborn; our 
present study reveals the close linkage between perinatal nicotine exposure and enhanced 
vulnerability to HIE, which further mirrors the notion of developmental origins of health 
and disease and also offer a feasible interventional target for prevention or attenuation of 
HIE. More importantly, our present study reveals its underlying epigenetic mechanism at 
the molecular level: nicotine exposure causes heightened methylation status of a single 
CpG-52 locus adjacent to TATA element at AT2R promoter, significantly inhibits binding 
activity of TBP and recruiting an inhibiting MeCP2 at promoter region, suppresses AT2R 
mRNA and protein abundance in male neonatal rat brain and results in enhanced 
vulnerability to HIE brain injury; inhibiting methylation of CpG-52 locus with 5-Aza 
(ICV) successfully reverses nicotine induced pathological consequences. This not only 
further enhances our understanding the pathophysiology of HIE but also provides us with 
another promising interventional targets although epigenetic pharmacological 
manipulations is just at the beginning and is mainly tested in animal studies. Because of 
current deficiency in potent and effective therapy, the prognosis and outcome for most 
neonatal HIE are less than optimal at the best, more exploring and investigations on its 
epigenetic mechanisms and intervention strategy should be warranted, which may confer 
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us a further hopeful future in the management of such a catastrophic disease of neonatal 
HIE.  
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